{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:51Z","timestamp":1789450491446,"version":"build-2803163510"},"reference-count":351,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32400781"],"award-info":[{"award-number":["32400781"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"President Foundation of Baiyun District People's Hospital of Guangzhou","award":["No. BYYZ25014"],"award-info":[{"award-number":["No. BYYZ25014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lewy body dementia (LBD) is a neurodegenerative disorder characterized by a combination of progressive dementia and spontaneous parkinsonian symptoms. As the second most prevalent form of neurodegenerative dementia after Alzheimer\u2019s disease (AD), LBD necessitates a deeper understanding of its pathogenesis to enable the development of targeted therapeutic interventions. While numerous reviews focus on documenting the clinical manifestations and therapeutic modalities for LBD, animal models provide valuable insights into the underlying mechanisms and potential therapeutic strategies. In this review, we systematically analyze the hallmarks of LBD pathogenesis, genetic risk factors, clinical features, and treatment strategies. Importantly, we emphasize and critically evaluate the pivotal role of animal models in LBD research in advancing our understanding of this disorder, offering a comprehensive framework to elucidate the interactions among misfolded proteins and their role in LBD pathogenesis. Our review proposes new directions for LBD therapeutic management and facilitates the development of innovative pharmacological interventions.<\/jats:p>","DOI":"10.1186\/s13024-025-00879-0","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T12:30:32Z","timestamp":1755001832000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid \u03b2, tau, and \u03b1-synuclein"],"prefix":"10.1186","volume":"20","author":[{"given":"Jingfeng","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3385-0138","authenticated-orcid":false,"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"879_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1192\/bjp.180.3.270","volume":"180","author":"T Stevens","year":"2002","unstructured":"Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C. Islington study of dementia subtypes in the community. Br J Psychiatry. 2002;180:270\u20136.","journal-title":"Br J Psychiatry"},{"issue":"6","key":"879_CR2","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp.74.6.720","volume":"74","author":"T Rahkonen","year":"2003","unstructured":"Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry. 2003;74(6):720\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"879_CR3","first-page":"185","volume":"3","author":"K Kosaka","year":"1984","unstructured":"Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree\u2013a new disease? Clin Neuropathol. 1984;3(5):185\u201392.","journal-title":"Clin Neuropathol"},{"issue":"1","key":"879_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","volume":"9","author":"M Goedert","year":"2013","unstructured":"Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13\u201324.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"879_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1136\/jnnp.2008.155481","volume":"80","author":"Y Matsui","year":"2009","unstructured":"Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, Ninomiya T, et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry. 2009;80(4):366\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"879_CR6","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1017\/cjn.2016.2","volume":"43","author":"DB Hogan","year":"2016","unstructured":"Hogan DB, Fiest KM, Roberts JI, Maxwell CJ, Dykeman J, Pringsheim T, et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci. 2016;43(Suppl 1):S83\u201395.","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"879_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88\u2013100.","journal-title":"Neurology"},{"issue":"9","key":"879_CR8","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrn3549","volume":"14","author":"DJ Irwin","year":"2013","unstructured":"Irwin DJ, Lee VM, Trojanowski JQ. Parkinson\u2019s disease dementia: convergence of \u03b1-synuclein, Tau and amyloid-\u03b2 pathologies. Nat Rev Neurosci. 2013;14(9):626\u201336.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"879_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41582-018-0107-7","volume":"15","author":"NA Arnaoutoglou","year":"2019","unstructured":"Arnaoutoglou NA, O\u2019Brien JT, Underwood BR. Dementia with Lewy bodies - from scientific knowledge to clinical insights. Nat Rev Neurol. 2019;15(2):103\u201312.","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"879_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13195-014-0073-2","volume":"6","author":"WS Kim","year":"2014","unstructured":"Kim WS, K\u00e5gedal K, Halliday GM. Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther. 2014;6(5):73.","journal-title":"Alzheimers Res Ther"},{"key":"879_CR11","doi-asserted-by":"publisher","first-page":"123487","DOI":"10.1016\/j.jns.2025.123487","volume":"472","author":"SKS Ting","year":"2025","unstructured":"Ting SKS, Saffari SE, Hameed S, Li WS, Mukesh Shah J, Chiew HJ, et al. Clinical characteristics of pathological confirmed DLB without parkinsonism. J Neurol Sci. 2025;472:123487.","journal-title":"J Neurol Sci"},{"issue":"6","key":"879_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837\u201344.","journal-title":"Mov Disord"},{"issue":"5","key":"879_CR13","doi-asserted-by":"publisher","first-page":"e209699","DOI":"10.1212\/WNL.0000000000209699","volume":"103","author":"J Gallagher","year":"2024","unstructured":"Gallagher J, Gochanour C, Caspell-Garcia C, Dobkin RD, Aarsland D, Alcalay RN, et al. Long-Term dementia risk in Parkinson disease. Neurology. 2024;103(5):e209699.","journal-title":"Neurology"},{"issue":"4","key":"879_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","volume":"36","author":"LA Hershey","year":"2019","unstructured":"Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with Lewy bodies. Drugs Aging. 2019;36(4):309\u201319.","journal-title":"Drugs Aging"},{"issue":"20","key":"879_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1212\/WNL.0000000000009433","volume":"94","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Emre M. Dementia with Lewy bodies and Parkinson disease dementia: more different than similar? Neurology. 2020;94(20):858\u20139.","journal-title":"Neurology"},{"issue":"17","key":"879_CR16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ, Blanc F, Boeve BF, Fujishiro H, et al. Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology. 2020;94(17):743\u201355.","journal-title":"Neurology"},{"issue":"1","key":"879_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12916-018-1016-8","volume":"16","author":"KA Jellinger","year":"2018","unstructured":"Jellinger KA, Korczyn AD. Are dementia with Lewy bodies and Parkinson\u2019s disease dementia the same disease? BMC Med. 2018;16(1):34.","journal-title":"BMC Med"},{"issue":"5","key":"879_CR18","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00702-011-0641-6","volume":"118","author":"GM Halliday","year":"2011","unstructured":"Halliday GM, Song YJ, Harding AJ. Striatal \u03b2-amyloid in dementia with Lewy bodies but not Parkinson\u2019s disease. J Neural Transm (Vienna). 2011;118(5):713\u20139.","journal-title":"J Neural Transm (Vienna)"},{"issue":"4\u20135","key":"879_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.brainresbull.2009.06.018","volume":"80","author":"E K\u00f6vari","year":"2009","unstructured":"K\u00f6vari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull. 2009;80(4\u20135):203\u201310.","journal-title":"Brain Res Bull"},{"issue":"8","key":"879_CR20","doi-asserted-by":"publisher","first-page":"e0202044","DOI":"10.1371\/journal.pone.0202044","volume":"13","author":"V Larsson","year":"2018","unstructured":"Larsson V, Torisson G, Londos E. Relative survival in patients with dementia with Lewy bodies and Parkinson\u2019s disease dementia. PLoS ONE. 2018;13(8):e0202044.","journal-title":"PLoS ONE"},{"issue":"7","key":"879_CR21","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol. 2010;9(7):702\u201316.","journal-title":"Lancet Neurol"},{"issue":"12","key":"879_CR22","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1212\/01.WNL.0000165987.89198.65","volume":"64","author":"ML Kraybill","year":"2005","unstructured":"Kraybill ML, Larson EB, Tsuang DW, Teri L, McCormick WC, Bowen JD, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology. 2005;64(12):2069\u201373.","journal-title":"Neurology"},{"issue":"4","key":"879_CR23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13854040500376831","volume":"20","author":"TJ Ferman","year":"2006","unstructured":"Ferman TJ, Smith GE, Boeve BF, Graff-Radford NR, Lucas JA, Knopman DS, et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer\u2019s disease. Clin Neuropsychol. 2006;20(4):623\u201336.","journal-title":"Clin Neuropsychol"},{"issue":"2","key":"879_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000097791","volume":"23","author":"TA Crowell","year":"2007","unstructured":"Crowell TA, Luis CA, Cox DE, Mullan M. Neuropsychological comparison of Alzheimer\u2019s disease and dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2007;23(2):120\u20135.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"5","key":"879_CR25","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/gps.389","volume":"16","author":"D Aarsland","year":"2001","unstructured":"Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson\u2019s disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528\u201336.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"14","key":"879_CR26","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1017\/S0033291718003161","volume":"49","author":"CL Eversfield","year":"2019","unstructured":"Eversfield CL, Orton LD. Auditory and visual hallucination prevalence in Parkinson\u2019s disease and dementia with Lewy bodies: a systematic review and meta-analysis. Psychol Med. 2019;49(14):2342\u201353.","journal-title":"Psychol Med"},{"key":"879_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2019.01.005","volume":"50","author":"C Mueller","year":"2019","unstructured":"Mueller C, Soysal P, Rongve A, Isik AT, Thompson T, Maggi S, et al. Survival time and differences between dementia with Lewy bodies and Alzheimer\u2019s disease following diagnosis: A meta-analysis of longitudinal studies. Ageing Res Rev. 2019;50:72\u201380.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"879_CR28","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.3233\/JAD-215587","volume":"86","author":"MJ Armstrong","year":"2022","unstructured":"Armstrong MJ, Song S, Kurasz AM, Li Z. Predictors of mortality in individuals with dementia in the National Alzheimer\u2019s coordinating center. J Alzheimers Dis. 2022;86(4):1935\u201346.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"879_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3233\/JAD-170274","volume":"59","author":"R Skogseth","year":"2017","unstructured":"Skogseth R, Hortob\u00e1gyi T, Soennesyn H, Chwiszczuk L, Ffytche D, Rongve A, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies versus neuropathology. J Alzheimers Dis. 2017;59(4):1139\u201352.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"879_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/jnnp-2017-316844","volume":"89","author":"G Rizzo","year":"2018","unstructured":"Rizzo G, Arcuti S, Copetti M, Alessandria M, Savica R, Fontana A, et al. Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(4):358\u201366.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"879_CR31","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neuint.2009.02.017","volume":"55","author":"K Koopman","year":"2009","unstructured":"Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer\u2019s disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int. 2009;55(4):214\u20138.","journal-title":"Neurochem Int"},{"issue":"5","key":"879_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2017-316385","volume":"89","author":"O Bousiges","year":"2018","unstructured":"Bousiges O, Bombois S, Schraen S, Wallon D, Quillard MM, Gabelle A, et al. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease at the prodromal stage. J Neurol Neurosurg Psychiatry. 2018;89(5):467\u201375.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"879_CR33","doi-asserted-by":"publisher","first-page":"e1009","DOI":"10.1212\/WNL.0000000000201647","volume":"100","author":"M Kurihara","year":"2023","unstructured":"Kurihara M, Komatsu H, Sengoku R, Shibukawa M, Morimoto S, Matsubara T, et al. CSF P-Tau181 and other biomarkers in patients with neuronal intranuclear inclusion disease. Neurology. 2023;100(10):e1009\u201319.","journal-title":"Neurology"},{"issue":"1","key":"879_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40478-024-01758-3","volume":"12","author":"M Kurihara","year":"2024","unstructured":"Kurihara M, Matsubara T, Morimoto S, Arakawa A, Ohse K, Kanemaru K, et al. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and A\u03b242 in Alzheimer\u2019s disease and other neurodegenerative diseases. Acta Neuropathol Commun. 2024;12(1):48.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"879_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3233\/JAD-150731","volume":"51","author":"O Bousiges","year":"2016","unstructured":"Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, et al. Diagnostic value of cerebrospinal fluid biomarkers (Phospho-Tau181, total-Tau, A\u03b242, and A\u03b240) in prodromal stage of Alzheimer\u2019s disease and dementia with Lewy bodies. J Alzheimers Dis. 2016;51(4):1069\u201383.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"879_CR36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/156720510791383796","volume":"7","author":"PE Spies","year":"2010","unstructured":"Spies PE, Slats D, Sj\u00f6gren JM, Kremer BP, Verhey FR, Rikkert MG, et al. The cerebrospinal fluid amyloid beta42\/40 ratio in the differentiation of Alzheimer\u2019s disease from non-Alzheimer\u2019s dementia. Curr Alzheimer Res. 2010;7(5):470\u20136.","journal-title":"Curr Alzheimer Res"},{"issue":"2","key":"879_CR37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","volume":"88","author":"AW Lemstra","year":"2017","unstructured":"Lemstra AW, de Beer MH, Teunissen CE, Schreuder C, Scheltens P, van der Flier WM, et al. Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2017;88(2):113\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6645","key":"879_CR38","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340.","journal-title":"Nature"},{"issue":"2","key":"879_CR39","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ana.21291","volume":"63","author":"GW Ross","year":"2008","unstructured":"Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, et al. Association of olfactory dysfunction with risk for future Parkinson\u2019s disease. Ann Neurol. 2008;63(2):167\u201373.","journal-title":"Ann Neurol"},{"issue":"6","key":"879_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1212\/WNL.0b013e3181ec7fac","volume":"75","author":"DO Claassen","year":"2010","unstructured":"Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology. 2010;75(6):494\u20139.","journal-title":"Neurology"},{"issue":"9996","key":"879_CR41","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912.","journal-title":"Lancet"},{"key":"879_CR42","doi-asserted-by":"crossref","unstructured":"Fan TS, Liu SC, Wu RM. Alpha-Synuclein and cognitive decline in Parkinson disease. Life (Basel). 2021;11(11).","DOI":"10.3390\/life11111239"},{"issue":"12","key":"879_CR43","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1097\/00005072-199912000-00007","volume":"58","author":"KL Newell","year":"1999","unstructured":"Newell KL, Boyer P, Gomez-Tortosa E, Hobbs W, Hedley-Whyte ET, Vonsattel JP, et al. Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury. J Neuropathol Exp Neurol. 1999;58(12):1263\u20138.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"879_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.14698","volume":"150","author":"L Walker","year":"2019","unstructured":"Walker L, Stefanis L, Attems J. Clinical and neuropathological differences between Parkinson\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies - current issues and future directions. J Neurochem. 2019;150(5):467\u201374.","journal-title":"J Neurochem"},{"issue":"12","key":"879_CR45","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 2009;8(12):1150\u20137.","journal-title":"Lancet Neurol"},{"issue":"4","key":"879_CR46","first-page":"1141","volume":"58","author":"DFV P\u00eer\u015fcoveanu","year":"2017","unstructured":"P\u00eer\u015fcoveanu DFV, Pirici I, Tudoric\u0103 V, B\u0103l\u015feanu TA, Albu VC, Bondari S, et al. Tau protein in neurodegenerative diseases - a review. Rom J Morphol Embryol. 2017;58(4):1141\u201350.","journal-title":"Rom J Morphol Embryol"},{"issue":"2","key":"879_CR47","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/ana.25392","volume":"85","author":"D Coughlin","year":"2019","unstructured":"Coughlin D, Xie SX, Liang M, Williams A, Peterson C, Weintraub D, et al. Cognitive and pathological influences of Tau pathology in Lewy body disorders. Ann Neurol. 2019;85(2):259\u201371.","journal-title":"Ann Neurol"},{"issue":"11","key":"879_CR48","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1212\/WNL.0b013e3182698d4a","volume":"79","author":"M Petrou","year":"2012","unstructured":"Petrou M, Bohnen NI, M\u00fcller ML, Koeppe RA, Albin RL, Frey KA. A\u03b2-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology. 2012;79(11):1161\u20137.","journal-title":"Neurology"},{"issue":"3","key":"879_CR49","doi-asserted-by":"publisher","first-page":"fcab180","DOI":"10.1093\/braincomms\/fcab180","volume":"3","author":"R Biundo","year":"2021","unstructured":"Biundo R, Weis L, Fiorenzato E, Pistonesi F, Cagnin A, Bertoldo A, et al. The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study. Brain Commun. 2021;3(3):fcab180.","journal-title":"Brain Commun"},{"issue":"4","key":"879_CR50","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/bpa.12424","volume":"27","author":"KE McAleese","year":"2017","unstructured":"McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer\u2019s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27(4):472\u20139.","journal-title":"Brain Pathol"},{"key":"879_CR51","doi-asserted-by":"crossref","unstructured":"Foska A, Tsantzali I, Sideri E, Stefanou MI, Bakola E, Kitsos DK et al. Classical cerebrospinal fluid biomarkers in dementia with Lewy bodies. Med (Kaunas). 2022;58(5).","DOI":"10.3390\/medicina58050612"},{"issue":"6","key":"879_CR52","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","volume":"119","author":"TG Beach","year":"2010","unstructured":"Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White Iii CL, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119(6):689\u2013702.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"879_CR53","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.26191","volume":"30","author":"M Petrou","year":"2015","unstructured":"Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, M\u00fcller ML, et al. Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic review. Mov Disord. 2015;30(7):928\u201335.","journal-title":"Mov Disord"},{"issue":"7","key":"879_CR54","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al. Biomarkers for Alzheimer\u2019s disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov. 2010;9(7):560\u201374.","journal-title":"Nat Rev Drug Discov"},{"key":"879_CR55","unstructured":"Irwin DJ, Hurtig HI. The contribution of tau, Amyloid-Beta and Alpha-Synuclein pathology to dementia in Lewy body disorders. J Alzheimers Dis Parkinsonism. 2018;8(4)."},{"issue":"1","key":"879_CR56","doi-asserted-by":"publisher","first-page":"e13210","DOI":"10.1111\/bpa.13210","volume":"34","author":"S Ichimata","year":"2024","unstructured":"Ichimata S, Yoshida K, Li J, Rogaeva E, Lang AE, Kovacs GG. The molecular spectrum of amyloid-beta (A\u03b2) in neurodegenerative diseases beyond Alzheimer\u2019s disease. Brain Pathol. 2024;34(1):e13210.","journal-title":"Brain Pathol"},{"issue":"9","key":"879_CR57","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1212\/WNL.0b013e31822c9148","volume":"77","author":"TJ Ferman","year":"2011","unstructured":"Ferman TJ, Boeve BF, Smith GE, Lin SC, Silber MH, Pedraza O, et al. Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology. 2011;77(9):875\u201382.","journal-title":"Neurology"},{"issue":"6","key":"879_CR58","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/jnnp.2008.155895","volume":"80","author":"SS Williams","year":"2009","unstructured":"Williams SS, Williams J, Combrinck M, Christie S, Smith AD, McShane R. Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):667\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"879_CR59","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1474-4422(07)70057-1","volume":"6","author":"I McKeith","year":"2007","unstructured":"McKeith I, O\u2019Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305\u201313.","journal-title":"Lancet Neurol"},{"key":"879_CR60","doi-asserted-by":"publisher","first-page":"1395413","DOI":"10.3389\/fneur.2024.1395413","volume":"15","author":"DM O\u2019Shea","year":"2024","unstructured":"O\u2019Shea DM, Arkhipenko A, Galasko D, Goldman JG, Sheikh ZH, Petrides G, et al. Practical use of DAT SPECT imaging in diagnosing dementia with Lewy bodies: a US perspective of current guidelines and future directions. Front Neurol. 2024;15:1395413.","journal-title":"Front Neurol"},{"issue":"3","key":"879_CR61","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1212\/WNL.0000000000003512","volume":"88","author":"AJ Thomas","year":"2017","unstructured":"Thomas AJ, Attems J, Colloby SJ, O\u2019Brien JT, McKeith I, Walker R, et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology. 2017;88(3):276\u201383.","journal-title":"Neurology"},{"issue":"1","key":"879_CR62","doi-asserted-by":"publisher","first-page":"fcaa040","DOI":"10.1093\/braincomms\/fcaa040","volume":"2","author":"J Graff-Radford","year":"2020","unstructured":"Graff-Radford J, Lesnick TG, Savica R, Chen Q, Ferman TJ, Przybelski SA, et al. (18)F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Commun. 2020;2(1):fcaa040.","journal-title":"Brain Commun"},{"key":"879_CR63","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2020.12.009","volume":"99","author":"T Miyagawa","year":"2021","unstructured":"Miyagawa T, Przybelski SA, Maltais D, Min HK, Jordan L, Lesnick TG, et al. The value of multimodal imaging with (123)I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer\u2019s disease dementia. Neurobiol Aging. 2021;99:11\u20138.","journal-title":"Neurobiol Aging"},{"issue":"16","key":"879_CR64","doi-asserted-by":"publisher","first-page":"e1648","DOI":"10.1212\/WNL.0000000000200110","volume":"98","author":"T Matsubara","year":"2022","unstructured":"Matsubara T, Kameyama M, Tanaka N, Sengoku R, Orita M, Furuta K, et al. Autopsy validation of the diagnostic accuracy of (123)I-Metaiodobenzylguanidine myocardial scintigraphy for Lewy body disease. Neurology. 2022;98(16):e1648\u201359.","journal-title":"Neurology"},{"issue":"7","key":"879_CR65","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00259-024-06631-y","volume":"51","author":"M Cotta Ramusino","year":"2024","unstructured":"Cotta Ramusino M, Massa F, Festari C, Gandolfo F, Nicolosi V, Orini S, et al. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review. Eur J Nucl Med Mol Imaging. 2024;51(7):1876\u201390.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"879_CR66","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/jnen\/nlz047","volume":"78","author":"L Patterson","year":"2019","unstructured":"Patterson L, Firbank MJ, Colloby SJ, Attems J, Thomas AJ, Morris CM. Neuropathological changes in dementia with Lewy bodies and the cingulate Island sign. J Neuropathol Exp Neurol. 2019;78(8):717\u201324.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"879_CR67","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/jon.13068","volume":"33","author":"K Woyk","year":"2023","unstructured":"Woyk K, Sahlmann CO, Hansen N, Tim\u00e4us C, M\u00fcller SJ, Khadhraoui E, et al. Brain (18) F-FDG-PET and an optimized cingulate Island ratio to differentiate Lewy body dementia and Alzheimer\u2019s disease. J Neuroimaging. 2023;33(2):256\u201368.","journal-title":"J Neuroimaging"},{"issue":"10","key":"879_CR68","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2967\/jnumed.109.065870","volume":"50","author":"SM Lim","year":"2009","unstructured":"Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulate Island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50(10):1638\u201345.","journal-title":"J Nucl Med"},{"key":"879_CR69","doi-asserted-by":"crossref","unstructured":"Hamed M, Schraml F, Wilson J, Galvin J, Sabbagh MN. Occipital and cingulate hypometabolism are significantly Under-Reported on 18-Fluorodeoxyglucose positron emission tomography scans of patients with Lewy body dementia. J Alzheimers Dis Parkinsonism. 2018;8(1).","DOI":"10.1016\/j.jalz.2018.06.400"},{"key":"879_CR70","doi-asserted-by":"publisher","first-page":"102754","DOI":"10.1016\/j.nicl.2021.102754","volume":"31","author":"K Kantarci","year":"2021","unstructured":"Kantarci K, Boeve BF, Przybelski SA, Lesnick TG, Chen Q, Fields J, et al. FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. Neuroimage Clin. 2021;31:102754.","journal-title":"Neuroimage Clin"},{"key":"879_CR71","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3389\/fnagi.2018.00190","volume":"10","author":"JJ van der Zande","year":"2018","unstructured":"van der Zande JJ, Gouw AA, van Steenoven I, Scheltens P, Stam CJ, Lemstra AW. EEG characteristics of dementia with Lewy bodies, Alzheimer\u2019s disease and mixed pathology. Front Aging Neurosci. 2018;10:190.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"879_CR72","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3233\/JAD-160435","volume":"54","author":"L Bonanni","year":"2016","unstructured":"Bonanni L, Franciotti R, Nobili F, Kramberger MG, Taylor JP, Garcia-Ptacek S, et al. EEG markers of dementia with Lewy bodies: A multicenter cohort study. J Alzheimers Dis. 2016;54(4):1649\u201357.","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"879_CR73","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.sleep.2012.10.015","volume":"14","author":"BF Boeve","year":"2013","unstructured":"Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14(8):754\u201362.","journal-title":"Sleep Med"},{"issue":"12","key":"879_CR74","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22(12):1689\u2013707. quiz 1837.","journal-title":"Mov Disord"},{"issue":"10004","key":"879_CR75","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Z Walker","year":"2015","unstructured":"Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet. 2015;386(10004):1683\u201397.","journal-title":"Lancet"},{"issue":"1","key":"879_CR76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0014-5793(94)00395-5","volume":"345","author":"R Jakes","year":"1994","unstructured":"Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994;345(1):27\u201332.","journal-title":"FEBS Lett"},{"issue":"16","key":"879_CR77","doi-asserted-by":"publisher","first-page":"9443","DOI":"10.1074\/jbc.273.16.9443","volume":"273","author":"WS Davidson","year":"1998","unstructured":"Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273(16):9443\u20139.","journal-title":"J Biol Chem"},{"issue":"5454","key":"879_CR78","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1126\/science.287.5454.864","volume":"287","author":"M Verhage","year":"2000","unstructured":"Verhage M, Maia AS, Plomp JJ, Brussaard AB, Heeroma JH, Vermeer H, et al. Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science. 2000;287(5454):864\u20139.","journal-title":"Science"},{"issue":"3","key":"879_CR79","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.cell.2005.09.028","volume":"123","author":"S Chandra","year":"2005","unstructured":"Chandra S, Gallardo G, Fern\u00e1ndez-Chac\u00f3n R, Schl\u00fcter OM, S\u00fcdhof TC. Alpha-synuclein cooperates with cspalpha in preventing neurodegeneration. Cell. 2005;123(3):383\u201396.","journal-title":"Cell"},{"issue":"5999","key":"879_CR80","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9 J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, S\u00fcdhof TC. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329(5999):1663\u20137.","journal-title":"Science"},{"issue":"5","key":"879_CR81","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s10024-003-7080-9","volume":"7","author":"R Raghavan","year":"2004","unstructured":"Raghavan R, Kruijff L, Sterrenburg MD, Rogers BB, Hladik CL, White CL 3. Alpha-synuclein expression in the developing human brain. Pediatr Dev Pathol. 2004;7(5):506\u201316.","journal-title":"Pediatr Dev Pathol"},{"issue":"5321","key":"879_CR82","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276(5321):2045\u20137.","journal-title":"Science"},{"issue":"2","key":"879_CR83","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kr\u00fcger","year":"1998","unstructured":"Kr\u00fcger R, Kuhn W, M\u00fcller T, Woitalla D, Graeber M, K\u00f6sel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet. 1998;18(2):106\u20138.","journal-title":"Nat Genet"},{"issue":"2","key":"879_CR84","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ana.10795","volume":"55","author":"JJ Zarranz","year":"2004","unstructured":"Zarranz JJ, Alegre J, G\u00f3mez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55(2):164\u201373.","journal-title":"Ann Neurol"},{"issue":"6","key":"879_CR85","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/mds.25421","volume":"28","author":"S Appel-Cresswell","year":"2013","unstructured":"Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson\u2019s disease. Mov Disord. 2013;28(6):811\u20133.","journal-title":"Mov Disord"},{"issue":"4","key":"879_CR86","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.23894","volume":"73","author":"S Lesage","year":"2013","unstructured":"Lesage S, Anheim M, Letournel F, Bousset L, Honor\u00e9 A, Rozas N, et al. G51D \u03b1-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol. 2013;73(4):459\u201371.","journal-title":"Ann Neurol"},{"key":"879_CR87","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.nbd.2015.12.018","volume":"88","author":"DE Mor","year":"2016","unstructured":"Mor DE, Ugras SE, Daniels MJ, Ischiropoulos H. Dynamic structural flexibility of \u03b1-synuclein. Neurobiol Dis. 2016;88:66\u201374.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"879_CR88","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14(3):176.","journal-title":"Cell Death Dis"},{"issue":"6","key":"879_CR89","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1016\/j.bbagen.2014.02.013","volume":"1840","author":"N Plotegher","year":"2014","unstructured":"Plotegher N, Gratton E, Bubacco L. Number and brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim Biophys Acta. 2014;1840(6):2014\u201324.","journal-title":"Biochim Biophys Acta"},{"issue":"342","key":"879_CR90","doi-asserted-by":"crossref","first-page":"342ra378","DOI":"10.1126\/scitranslmed.aaf3634","volume":"8","author":"R Di Maio","year":"2016","unstructured":"Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, et al. \u03b1-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease. Sci Transl Med. 2016;8(342):342ra378.","journal-title":"Sci Transl Med"},{"issue":"1","key":"879_CR91","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann MHR, Angelova PR, Horrocks MH, Choi ML, Rodrigues M, Baev AY, et al. \u03b1-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat Commun. 2018;9(1):2293.","journal-title":"Nat Commun"},{"issue":"6357","key":"879_CR92","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1126\/science.aam9080","volume":"357","author":"LF Burbulla","year":"2017","unstructured":"Burbulla LF, Song P, Mazzulli JR, Zampese E, Wong YC, Jeon S, et al. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease. Science. 2017;357(6357):1255\u201361.","journal-title":"Science"},{"key":"879_CR93","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1113\/jphysiol.1993.sp019742","volume":"466","author":"S Nedergaard","year":"1993","unstructured":"Nedergaard S, Flatman JA, Engberg I. Nifedipine- and omega-conotoxin-sensitive Ca2\u2009+\u2009conductances in guinea-pig substantia Nigra Pars compacta neurones. J Physiol. 1993;466:727\u201347.","journal-title":"J Physiol"},{"issue":"11","key":"879_CR94","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.bbabio.2009.05.011","volume":"1787","author":"RS Balaban","year":"2009","unstructured":"Balaban RS. The role of Ca(2+) signaling in the coordination of mitochondrial ATP production with cardiac work. Biochim Biophys Acta. 2009;1787(11):1334\u201341.","journal-title":"Biochim Biophys Acta"},{"issue":"49","key":"879_CR95","doi-asserted-by":"publisher","first-page":"15414","DOI":"10.1523\/JNEUROSCI.4742-09.2009","volume":"29","author":"I Putzier","year":"2009","unstructured":"Putzier I, Kullmann PH, Horn JP, Levitan ES. Cav1.3 channel voltage dependence, not Ca2\u2009+\u2009selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J Neurosci. 2009;29(49):15414\u20139.","journal-title":"J Neurosci"},{"issue":"Pt 11","key":"879_CR96","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1093\/brain\/awh625","volume":"128","author":"CF Orr","year":"2005","unstructured":"Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson\u2019s disease. Brain. 2005;128(Pt 11):2665\u201374.","journal-title":"Brain"},{"issue":"4615","key":"879_CR97","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1126\/science.6308771","volume":"221","author":"JE Goldman","year":"1983","unstructured":"Goldman JE, Yen SH, Chiu FC, Peress NS. Lewy bodies of Parkinson\u2019s disease contain neurofilament antigens. Science. 1983;221(4615):1082\u20134.","journal-title":"Science"},{"issue":"8713","key":"879_CR98","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/0140-6736(90)92075-S","volume":"336","author":"J Lowe","year":"1990","unstructured":"Lowe J, Landon M, Pike I, Spendlove I, McDermott H, Mayer RJ. Dementia with beta-amyloid deposition: involvement of alpha B-crystallin supports two main diseases. Lancet. 1990;336(8713):515\u20136.","journal-title":"Lancet"},{"issue":"11","key":"879_CR99","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1046\/j.1460-9568.2002.02301.x","volume":"16","author":"KS McNaught","year":"2002","unstructured":"McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci. 2002;16(11):2136\u201348.","journal-title":"Eur J Neurosci"},{"issue":"5","key":"879_CR100","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat Med. 2008;14(5):504\u20136.","journal-title":"Nat Med"},{"key":"879_CR101","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biochi.2021.09.012","volume":"192","author":"J Gadhavi","year":"2022","unstructured":"Gadhavi J, Patel M, Bhatia D, Gupta S. Neurotoxic or neuroprotective: Post-translational modifications of \u03b1-synuclein at the cross-roads of functions. Biochimie. 2022;192:38\u201350.","journal-title":"Biochimie"},{"issue":"40","key":"879_CR102","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in Familial and sporadic Lewy body disease. J Biol Chem. 2006;281(40):29739\u201352.","journal-title":"J Biol Chem"},{"issue":"8","key":"879_CR103","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","volume":"29","author":"C Quadalti","year":"2023","unstructured":"Quadalti C, Palmqvist S, Hall S, Rossi M, Mammana A, Janelidze S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29(8):1964\u201370.","journal-title":"Nat Med"},{"issue":"6106","key":"879_CR104","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/325733a0","volume":"325","author":"J Kang","year":"1987","unstructured":"Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325(6106):733\u20136.","journal-title":"Nature"},{"issue":"1","key":"879_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0301-0082(03)00089-3","volume":"70","author":"PR Turner","year":"2003","unstructured":"Turner PR, O\u2019Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol. 2003;70(1):1\u201332.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"879_CR106","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/S0014-5793(00)02076-7","volume":"483","author":"J Nunan","year":"2000","unstructured":"Nunan J, Small DH. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett. 2000;483(1):6\u201310.","journal-title":"FEBS Lett"},{"issue":"4959","key":"879_CR107","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1126\/science.2111583","volume":"248","author":"FS Esch","year":"1990","unstructured":"Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science. 1990;248(4959):1122\u20134.","journal-title":"Science"},{"issue":"5","key":"879_CR108","first-page":"1121","volume":"115","author":"S Gandy","year":"2005","unstructured":"Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J Clin Invest. 2005;115(5):1121\u20139.","journal-title":"J Clin Invest"},{"issue":"4","key":"879_CR109","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1074\/jbc.272.4.2038","volume":"272","author":"M Hoshi","year":"1997","unstructured":"Hoshi M, Takashima A, Murayama M, Yasutake K, Yoshida N, Ishiguro K, et al. Nontoxic amyloid beta peptide 1\u201342 suppresses acetylcholine synthesis. Possible role in cholinergic dysfunction in Alzheimer\u2019s disease. J Biol Chem. 1997;272(4):2038\u201341.","journal-title":"J Biol Chem"},{"issue":"Pt 5","key":"879_CR110","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/brain\/awl063","volume":"129","author":"M Bibl","year":"2006","unstructured":"Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, et al. CSF amyloid-beta-peptides in Alzheimer\u2019s disease, dementia with Lewy bodies and Parkinson\u2019s disease dementia. Brain. 2006;129(Pt 5):1177\u201387.","journal-title":"Brain"},{"issue":"1","key":"879_CR111","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13195-019-0537-5","volume":"11","author":"I van Steenoven","year":"2019","unstructured":"van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Amyloid-\u03b2 peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimers Res Ther. 2019;11(1):83.","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"879_CR112","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","volume":"69","author":"PT Kotzbauer","year":"2012","unstructured":"Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, et al. Pathologic accumulation of \u03b1-synuclein and A\u03b2 in Parkinson disease patients with dementia. Arch Neurol. 2012;69(10):1326\u201331.","journal-title":"Arch Neurol"},{"issue":"3","key":"879_CR113","doi-asserted-by":"publisher","first-page":"e0171802","DOI":"10.1371\/journal.pone.0171802","volume":"12","author":"S Liu","year":"2017","unstructured":"Liu S, Wang XD, Wang Y, Shi Z, Cai L, Liu S, et al. Clinical and neuroimaging characteristics of Chinese dementia with Lewy bodies. PLoS ONE. 2017;12(3):e0171802.","journal-title":"PLoS ONE"},{"key":"879_CR114","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer\u2019s disease. Nat Rev Dis Primers. 2015;1:15056.","journal-title":"Nat Rev Dis Primers"},{"issue":"5594","key":"879_CR115","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1126\/science.1074069","volume":"298","author":"DJ Selkoe","year":"2002","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002;298(5594):789\u201391.","journal-title":"Science"},{"issue":"6","key":"879_CR116","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358\u201372.","journal-title":"Nat Rev Neurosci"},{"issue":"6","key":"879_CR117","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719\u201332.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"879_CR118","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/0896-6273(89)90210-9","volume":"3","author":"M Goedert","year":"1989","unstructured":"Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer\u2019s disease. Neuron. 1989;3(4):519\u201326.","journal-title":"Neuron"},{"issue":"9 Pt B","key":"879_CR119","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1016\/j.bbadis.2018.04.023","volume":"1864","author":"JR Welden","year":"2018","unstructured":"Welden JR, van Doorn J, Nelson PT, Stamm S. The human MAPT locus generates circular RNAs. Biochim Biophys Acta Mol Basis Dis. 2018;1864(9 Pt B):2753\u201360.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"13","key":"879_CR120","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1002\/j.1460-2075.1990.tb07870.x","volume":"9","author":"M Goedert","year":"1990","unstructured":"Goedert M, Jakes R. Expression of separate isoforms of human Tau protein: correlation with the Tau pattern in brain and effects on tubulin polymerization. Embo J. 1990;9(13):4225\u201330.","journal-title":"Embo J"},{"issue":"1","key":"879_CR121","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17(1):5\u201321.","journal-title":"Nat Rev Neurosci"},{"key":"879_CR122","doi-asserted-by":"publisher","first-page":"102726","DOI":"10.1016\/j.arr.2025.102726","volume":"107","author":"AG Mukherjee","year":"2025","unstructured":"Mukherjee AG, Mishra S, Gopalakrishnan AV, Kannampuzha S, Murali R, Wanjari UR, et al. Unraveling the mystery of citrate transporters in Alzheimer\u2019s disease: an updated review. Ageing Res Rev. 2025;107:102726.","journal-title":"Ageing Res Rev"},{"issue":"Pt 10","key":"879_CR123","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1093\/brain\/awv236","volume":"138","author":"H Braak","year":"2015","unstructured":"Braak H, Del Tredici K. The preclinical phase of the pathological process underlying sporadic Alzheimer\u2019s disease. Brain. 2015;138(Pt 10):2814\u201333.","journal-title":"Brain"},{"issue":"12","key":"879_CR124","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1073\/pnas.91.12.5562","volume":"91","author":"AC Alonso","year":"1994","unstructured":"Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated Tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91(12):5562\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"879_CR125","doi-asserted-by":"crossref","unstructured":"Rahman MW, Sharma P, Chattopadhyay T, Saroja SR. Distinct neuronal vulnerability and metabolic dysfunctions are characteristic features of fast-progressing Alzheimer\u2019s patients with Lewy bodies. J Biol Chem. 2025:108396.","DOI":"10.1016\/j.jbc.2025.108396"},{"issue":"3","key":"879_CR126","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00401-007-0261-2","volume":"114","author":"H Nakashima-Yasuda","year":"2007","unstructured":"Nakashima-Yasuda H, Uryu K, Robinson J, Xie SX, Hurtig H, Duda JE, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114(3):221\u20139.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"879_CR127","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s13311-015-0338-x","volume":"12","author":"EL Scotter","year":"2015","unstructured":"Scotter EL, Chen HJ, Shaw CE. TDP-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. Neurotherapeutics. 2015;12(2):352\u201363.","journal-title":"Neurotherapeutics"},{"issue":"8","key":"879_CR128","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00439-016-1683-5","volume":"135","author":"T Geuens","year":"2016","unstructured":"Geuens T, Bouhy D, Timmerman V. The HnRNP family: insights into their role in health and disease. Hum Genet. 2016;135(8):851\u201367.","journal-title":"Hum Genet"},{"issue":"1","key":"879_CR129","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awab285","volume":"145","author":"N Riva","year":"2022","unstructured":"Riva N, Gentile F, Cerri F, Gallia F, Podini P, Dina G, et al. Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022;145(1):276\u201384.","journal-title":"Brain"},{"key":"879_CR130","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.brainres.2007.09.048","volume":"1184","author":"S Higashi","year":"2007","unstructured":"Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, et al. Concurrence of TDP-43, Tau and alpha-synuclein pathology in brains of Alzheimer\u2019s disease and dementia with Lewy bodies. Brain Res. 2007;1184:284\u201394.","journal-title":"Brain Res"},{"issue":"6","key":"879_CR131","doi-asserted-by":"publisher","first-page":"fcae442","DOI":"10.1093\/braincomms\/fcae442","volume":"6","author":"K Gawor","year":"2024","unstructured":"Gawor K, Tom\u00e9 SO, Vandenberghe R, Van Damme P, Vandenbulcke M, Otto M, et al. Amygdala-predominant \u03b1-synuclein pathology is associated with exacerbated hippocampal neuron loss in Alzheimer\u2019s disease. Brain Commun. 2024;6(6):fcae442.","journal-title":"Brain Commun"},{"issue":"1","key":"879_CR132","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s40478-024-01914-9","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Luo C, Jiang Y, Hu T, Lin B, Xie Y, et al. Decoding TDP-43: the molecular chameleon of neurodegenerative diseases. Acta Neuropathol Commun. 2024;12(1):205.","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"879_CR133","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00401-014-1358-z","volume":"129","author":"N Aoki","year":"2015","unstructured":"Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R, et al. Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP type A. Acta Neuropathol. 2015;129(1):53\u201364.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"879_CR134","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bpa.12505","volume":"28","author":"VD Smith","year":"2018","unstructured":"Smith VD, Bachstetter AD, Ighodaro E, Roberts K, Abner EL, Fardo DW, et al. Overlapping but distinct TDP-43 and Tau pathologic patterns in aged hippocampi. Brain Pathol. 2018;28(2):264\u201373.","journal-title":"Brain Pathol"},{"issue":"4","key":"879_CR135","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3233\/JAD-191040","volume":"73","author":"M Buciuc","year":"2020","unstructured":"Buciuc M, Wennberg AM, Weigand SD, Murray ME, Senjem ML, Spychalla AJ, et al. Effect modifiers of TDP-43-Associated hippocampal atrophy rates in patients with Alzheimer\u2019s disease neuropathological changes. J Alzheimers Dis. 2020;73(4):1511\u201323.","journal-title":"J Alzheimers Dis"},{"key":"879_CR136","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbi.2015.10.012","volume":"55","author":"WJ Streit","year":"2016","unstructured":"Streit WJ, Xue QS. Microglia in dementia with Lewy bodies. Brain Behav Immun. 2016;55:191\u2013201.","journal-title":"Brain Behav Immun"},{"issue":"12","key":"879_CR137","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.parkreldis.2015.10.009","volume":"21","author":"A Surendranathan","year":"2015","unstructured":"Surendranathan A, Rowe JB, O\u2019Brien JT. Neuroinflammation in Lewy body dementia. Parkinsonism Relat Disord. 2015;21(12):1398\u2013406.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"879_CR138","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp-2017-317134","volume":"89","author":"E King","year":"2018","unstructured":"King E, O\u2019Brien JT, Donaghy P, Morris C, Barnett N, Olsen K, et al. Peripheral inflammation in prodromal Alzheimer\u2019s and Lewy body dementias. J Neurol Neurosurg Psychiatry. 2018;89(4):339\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"879_CR139","doi-asserted-by":"publisher","first-page":"17578","DOI":"10.1038\/s41598-022-22400-z","volume":"12","author":"M Asghar","year":"2022","unstructured":"Asghar M, Odeh A, Fattahi AJ, Henriksson AE, Miglar A, Khosousi S, et al. Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson\u2019s disease and Lewy body dementia. Sci Rep. 2022;12(1):17578.","journal-title":"Sci Rep"},{"issue":"3","key":"879_CR140","first-page":"151","volume":"30","author":"M Spano","year":"2015","unstructured":"Spano M, Signorelli M, Vitaliani R, Aguglia E, Giometto B. The possible involvement of mitochondrial dysfunctions in lewy body dementia: a systematic review. Funct Neurol. 2015;30(3):151\u20138.","journal-title":"Funct Neurol"},{"issue":"4","key":"879_CR141","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/nan.12260","volume":"42","author":"JH Baek","year":"2016","unstructured":"Baek JH, Whitfield D, Howlett D, Francis P, Bereczki E, Ballard C, et al. Unfolded protein response is activated in Lewy body dementias. Neuropathol Appl Neurobiol. 2016;42(4):352\u201365.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"879_CR142","doi-asserted-by":"crossref","unstructured":"Surguchov A. \u03b1-Synuclein and mechanisms of epigenetic regulation. Brain Sci. 2023;13(1).","DOI":"10.3390\/brainsci13010150"},{"issue":"11","key":"879_CR143","doi-asserted-by":"publisher","first-page":"9031","DOI":"10.1074\/jbc.C110.212589","volume":"286","author":"P Desplats","year":"2011","unstructured":"Desplats P, Spencer B, Coffee E, Patel P, Michael S, Patrick C, et al. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem. 2011;286(11):9031\u20137.","journal-title":"J Biol Chem"},{"issue":"1","key":"879_CR144","doi-asserted-by":"publisher","first-page":"e718","DOI":"10.1038\/tp.2015.214","volume":"6","author":"JV Sanchez-Mut","year":"2016","unstructured":"Sanchez-Mut JV, Heyn H, Vidal E, Moran S, Sayols S, Delgado-Morales R, et al. Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns. Transl Psychiatry. 2016;6(1):e718.","journal-title":"Transl Psychiatry"},{"issue":"1","key":"879_CR145","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/s42003-022-03965-x","volume":"5","author":"X Shao","year":"2022","unstructured":"Shao X, Vishweswaraiah S, \u010cuperlovi\u0107-Culf M, Yilmaz A, Greenwood CMT, Surendra A, et al. Dementia with Lewy bodies post-mortem brains reveal differentially methylated CpG sites with biomarker potential. Commun Biol. 2022;5(1):1279.","journal-title":"Commun Biol"},{"issue":"1","key":"879_CR146","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1038\/s41467-022-32619-z","volume":"13","author":"L Pihlstr\u00f8m","year":"2022","unstructured":"Pihlstr\u00f8m L, Shireby G, Geut H, Henriksen SP, Rozemuller AJM, Tunold JA, et al. Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology. Nat Commun. 2022;13(1):4932.","journal-title":"Nat Commun"},{"issue":"1","key":"879_CR147","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pcn.12462","volume":"71","author":"Y Funahashi","year":"2017","unstructured":"Funahashi Y, Yoshino Y, Yamazaki K, Mori Y, Mori T, Ozaki Y, et al. DNA methylation changes at SNCA intron 1 in patients with dementia with Lewy bodies. Psychiatry Clin Neurosci. 2017;71(1):28\u201335.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"7","key":"879_CR148","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jalz.2018.02.005","volume":"14","author":"J Tulloch","year":"2018","unstructured":"Tulloch J, Leong L, Chen S, Keene CD, Millard SP, Shutes-David A, et al. APOE DNA methylation is altered in Lewy body dementia. Alzheimers Dement. 2018;14(7):889\u201394.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"879_CR149","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1038\/s41598-019-43458-2","volume":"9","author":"A Rongve","year":"2019","unstructured":"Rongve A, Witoelar A, Ruiz A, Athanasiu L, Abdelnour C, Clarimon J, et al. GBA and APOE \u03b54 associate with sporadic dementia with Lewy bodies in European genome wide association study. Sci Rep. 2019;9(1):7013.","journal-title":"Sci Rep"},{"key":"879_CR150","doi-asserted-by":"publisher","first-page":"562241","DOI":"10.3389\/fcell.2020.562241","volume":"8","author":"M Kiechle","year":"2020","unstructured":"Kiechle M, Grozdanov V, Danzer KM. The role of lipids in the initiation of \u03b1-Synuclein misfolding. Front Cell Dev Biol. 2020;8:562241.","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"879_CR151","doi-asserted-by":"publisher","first-page":"166203","DOI":"10.1016\/j.bbadis.2021.166203","volume":"1867","author":"X Huang","year":"2021","unstructured":"Huang X, Wang C, Chen L, Zhang T, Leung KL, Wong G. Human amyloid beta and \u03b1-synuclein co-expression in neurons impair behavior and recapitulate features for Lewy body dementia in caenorhabditis elegans. Biochim Biophys Acta Mol Basis Dis. 2021;1867(10):166203.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"879_CR152","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neurobiolaging.2016.08.027","volume":"49","author":"R Marin","year":"2017","unstructured":"Marin R, Fabelo N, Mart\u00edn V, Garcia-Esparcia P, Ferrer I, Quinto-Alemany D, et al. Anomalies occurring in lipid profiles and protein distribution in frontal cortex lipid rafts in dementia with Lewy bodies disclose neurochemical traits partially shared by Alzheimer\u2019s and Parkinson\u2019s diseases. Neurobiol Aging. 2017;49:52\u20139.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"879_CR153","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1006\/jmbi.2001.4538","volume":"307","author":"D Eliezer","year":"2001","unstructured":"Eliezer D, Kutluay E, Bussell R Jr., Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated States. J Mol Biol. 2001;307(4):1061\u201373.","journal-title":"J Mol Biol"},{"issue":"1","key":"879_CR154","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12017-021-08644-4","volume":"23","author":"JY Lee","year":"2021","unstructured":"Lee JY, Marian OC, Don AS. Defective lysosomal lipid catabolism as a common pathogenic mechanism for dementia. Neuromolecular Med. 2021;23(1):1\u201324.","journal-title":"Neuromolecular Med"},{"issue":"9","key":"879_CR155","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/mds.28617","volume":"36","author":"KB Andersen","year":"2021","unstructured":"Andersen KB, Hansen AK, Damholdt MF, Horsager J, Skjaerbaek C, Gottrup H, et al. Reduced synaptic density in patients with Lewy body dementia: an [(11) C]UCB-J PET imaging study. Mov Disord. 2021;36(9):2057\u201365.","journal-title":"Mov Disord"},{"issue":"4","key":"879_CR156","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/mds.27945","volume":"35","author":"M Huber","year":"2020","unstructured":"Huber M, Beyer L, Prix C, Sch\u00f6necker S, Palleis C, Rauchmann BS, et al. Metabolic correlates of dopaminergic loss in dementia with Lewy bodies. Mov Disord. 2020;35(4):595\u2013605.","journal-title":"Mov Disord"},{"issue":"11","key":"879_CR157","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1212\/01.wnl.0000191154.78131.f6","volume":"65","author":"R Hilker","year":"2005","unstructured":"Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65(11):1716\u201322.","journal-title":"Neurology"},{"issue":"1\u20133","key":"879_CR158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14789450.2024.2320807","volume":"21","author":"DB McClatchy","year":"2024","unstructured":"McClatchy DB. Quantitative analysis of proteostasis networks: are there applications for dementia? Expert Rev Proteom. 2024;21(1\u20133):1\u20133.","journal-title":"Expert Rev Proteom"},{"issue":"0","key":"879_CR159","first-page":"0","volume":"0","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selb\u00e6k G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the lancet standing commission. Lancet. 2024;0(0):0.","journal-title":"Lancet"},{"issue":"12","key":"879_CR160","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1212\/01.wnl.0000219812.20616.b3","volume":"66","author":"BK Woodruff","year":"2006","unstructured":"Woodruff BK, Graff-Radford NR, Ferman TJ, Dickson DW, DeLucia MW, Crook JE, et al. Family history of dementia is a risk factor for Lewy body disease. Neurology. 2006;66(12):1949\u201350.","journal-title":"Neurology"},{"issue":"1","key":"879_CR161","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1474-4422(17)30400-3","volume":"17","author":"R Guerreiro","year":"2018","unstructured":"Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez DG, Orme T, Eicher JD, et al. Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurol. 2018;17(1):64\u201374.","journal-title":"Lancet Neurol"},{"issue":"4852","key":"879_CR162","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.3283935","volume":"240","author":"RW Mahley","year":"1988","unstructured":"Mahley RW, Apolipoprotein E. Cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622\u201330.","journal-title":"Science"},{"key":"879_CR163","doi-asserted-by":"publisher","first-page":"102954","DOI":"10.1016\/j.ebiom.2020.102954","volume":"59","author":"AL Lumsden","year":"2020","unstructured":"Lumsden AL, Mulugeta A, Zhou A, Hypp\u00f6nen E. Apolipoprotein E (APOE) genotype-associated disease risks: a phenome-wide, registry-based, case-control study utilising the UK biobank. EBioMedicine. 2020;59:102954.","journal-title":"EBioMedicine"},{"issue":"6","key":"879_CR164","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1073\/pnas.050004797","volume":"97","author":"DM Holtzman","year":"2000","unstructured":"Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2000;97(6):2892\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"879_CR165","doi-asserted-by":"publisher","first-page":"23227","DOI":"10.1074\/jbc.M303365200","volume":"278","author":"H Saito","year":"2003","unstructured":"Saito H, Dhanasekaran P, Nguyen D, Holvoet P, Lund-Katz S, Phillips MC. Domain structure and lipid interaction in human apolipoproteins A-I and E, a general model. J Biol Chem. 2003;278(26):23227\u201332.","journal-title":"J Biol Chem"},{"issue":"7673","key":"879_CR166","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523\u20137.","journal-title":"Nature"},{"issue":"2","key":"879_CR167","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.neuron.2020.10.008","volume":"109","author":"Y Chen","year":"2021","unstructured":"Chen Y, Strickland MR, Soranno A, Holtzman DM, Apolipoprotein E. Structural insights and links to Alzheimer disease pathogenesis. Neuron. 2021;109(2):205\u201321.","journal-title":"Neuron"},{"issue":"12","key":"879_CR168","doi-asserted-by":"publisher","first-page":"e1182","DOI":"10.1212\/WNL.0000000000006212","volume":"91","author":"DW Dickson","year":"2018","unstructured":"Dickson DW, Heckman MG, Murray ME, Soto AI, Walton RL, Diehl NN, et al. APOE \u03b54 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91(12):e1182\u201395.","journal-title":"Neurology"},{"key":"879_CR169","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3389\/fnins.2017.00702","volume":"11","author":"T Nuriel","year":"2017","unstructured":"Nuriel T, Peng KY, Ashok A, Dillman AA, Figueroa HY, Apuzzo J, et al. The Endosomal-Lysosomal pathway is dysregulated by APOE4 expression in vivo. Front Neurosci. 2017;11:702.","journal-title":"Front Neurosci"},{"issue":"6","key":"879_CR170","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00401-022-02421-8","volume":"143","author":"Y Jin","year":"2022","unstructured":"Jin Y, Li F, Sonoustoun B, Kondru NC, Martens YA, Qiao W, et al. APOE4 exacerbates \u03b1-synuclein seeding activity and contributes to neurotoxicity in Alzheimer\u2019s disease with Lewy body pathology. Acta Neuropathol. 2022;143(6):641\u201362.","journal-title":"Acta Neuropathol"},{"key":"879_CR171","doi-asserted-by":"crossref","unstructured":"Davis AA, Inman CE, Wargel ZM, Dube U, Freeberg BM, Galluppi A et al. APOE genotype regulates pathology and disease progression in synucleinopathy. Sci Transl Med. 2020;12(529).","DOI":"10.1126\/scitranslmed.aay3069"},{"issue":"1","key":"879_CR172","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1038\/s41467-020-19264-0","volume":"11","author":"J Zhao","year":"2020","unstructured":"Zhao J, Fu Y, Yamazaki Y, Ren Y, Davis MD, Liu CC, et al. APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer\u2019s disease patient iPSC-derived cerebral organoids. Nat Commun. 2020;11(1):5540.","journal-title":"Nat Commun"},{"issue":"8","key":"879_CR173","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.neuron.2022.03.004","volume":"110","author":"YA Martens","year":"2022","unstructured":"Martens YA, Zhao N, Liu CC, Kanekiyo T, Yang AJ, Goate AM, et al. ApoE cascade hypothesis in the pathogenesis of Alzheimer\u2019s disease and related dementias. Neuron. 2022;110(8):1304\u201317.","journal-title":"Neuron"},{"issue":"1","key":"879_CR174","doi-asserted-by":"publisher","first-page":"108572","DOI":"10.1016\/j.celrep.2020.108572","volume":"34","author":"G Qi","year":"2021","unstructured":"Qi G, Mi Y, Shi X, Gu H, Brinton RD, Yin F. ApoE4 impairs Neuron-Astrocyte coupling of fatty acid metabolism. Cell Rep. 2021;34(1):108572.","journal-title":"Cell Rep"},{"key":"879_CR175","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1126\/scitranslmed.aaz4564","volume":"13","author":"G Sienski","year":"2021","unstructured":"Sienski G, Narayan P, Bonner JM, Kory N, Boland S, Arczewska AA, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. Sci Transl Med. 2021;13:583.","journal-title":"Sci Transl Med"},{"issue":"3","key":"879_CR176","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nn2058","volume":"11","author":"G Gallardo","year":"2008","unstructured":"Gallardo G, Schl\u00fcter OM, S\u00fcdhof TC. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci. 2008;11(3):301\u20138.","journal-title":"Nat Neurosci"},{"issue":"5","key":"879_CR177","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","volume":"101","author":"ME Belloy","year":"2019","unstructured":"Belloy ME, Napolioni V, Greicius MD. A quarter century of APOE and Alzheimer\u2019s disease: progress to date and the path forward. Neuron. 2019;101(5):820\u201338.","journal-title":"Neuron"},{"issue":"11","key":"879_CR178","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1084\/jem.20190980","volume":"216","author":"Y Shi","year":"2019","unstructured":"Shi Y, Manis M, Long J, Wang K, Sullivan PM, Remolina Serrano J, et al. Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216(11):2546\u201361.","journal-title":"J Exp Med"},{"issue":"5290","key":"879_CR179","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1126\/science.274.5290.1197","volume":"274","author":"MH Polymeropoulos","year":"1996","unstructured":"Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, et al. Mapping of a gene for Parkinson\u2019s disease to chromosome 4q21-q23. Science. 1996;274(5290):1197\u20139.","journal-title":"Science"},{"issue":"6","key":"879_CR180","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00439-008-0582-9","volume":"124","author":"N Pankratz","year":"2009","unstructured":"Pankratz N, Wilk JB, Latourelle JC, DeStefano AL, Halter C, Pugh EW, et al. Genomewide association study for susceptibility genes contributing to Familial Parkinson disease. Hum Genet. 2009;124(6):593\u2013605.","journal-title":"Hum Genet"},{"issue":"7","key":"879_CR181","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.4103\/1673-5374.300980","volume":"16","author":"J Dorszewska","year":"2021","unstructured":"Dorszewska J, Kowalska M, Prendecki M, Piekut T, Koz\u0142owska J, Kozubski W. Oxidative stress factors in Parkinson\u2019s disease. Neural Regen Res. 2021;16(7):1383\u201391.","journal-title":"Neural Regen Res"},{"issue":"2","key":"879_CR182","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41419-021-03441-0","volume":"12","author":"M Bi","year":"2021","unstructured":"Bi M, Du X, Jiao Q, Chen X, Jiang H. Expanding the role of proteasome homeostasis in Parkinson\u2019s disease: beyond protein breakdown. Cell Death Dis. 2021;12(2):154.","journal-title":"Cell Death Dis"},{"key":"879_CR183","doi-asserted-by":"crossref","unstructured":"Popova B, Galka D, H\u00e4ffner N, Wang D, Schmitt K, Valerius O et al. \u03b1-Synuclein decreases the abundance of proteasome subunits and alters ubiquitin conjugates in yeast. Cells. 2021;10(9).","DOI":"10.3390\/cells10092229"},{"issue":"1","key":"879_CR184","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41422-024-01022-2","volume":"35","author":"Q Xu","year":"2025","unstructured":"Xu Q, Wang H, Yang R, Tao Y, Wang Z, Zhang S, et al. \u03b1-Synuclein amyloid fibril directly binds to LC3B and suppresses SQSTM1\/p62-mediated selective autophagy. Cell Res. 2025;35(1):72\u20135.","journal-title":"Cell Res"},{"issue":"1","key":"879_CR185","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41531-022-00370-3","volume":"8","author":"MG Stykel","year":"2022","unstructured":"Stykel MG, Ryan SD. Nitrosative stress in Parkinson\u2019s disease. NPJ Parkinsons Dis. 2022;8(1):104.","journal-title":"NPJ Parkinsons Dis"},{"issue":"12","key":"879_CR186","doi-asserted-by":"publisher","first-page":"167992","DOI":"10.1016\/j.jmb.2023.167992","volume":"435","author":"T Sohrabi","year":"2023","unstructured":"Sohrabi T, Mirzaei-Behbahani B, Zadali R, Pirhaghi M, Morozova-Roche LA, Meratan AA. Common mechanisms underlying \u03b1-Synuclein-Induced mitochondrial dysfunction in Parkinson\u2019s disease. J Mol Biol. 2023;435(12):167992.","journal-title":"J Mol Biol"},{"issue":"6","key":"879_CR187","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1096\/fj.04-2751com","volume":"19","author":"W Zhang","year":"2005","unstructured":"Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson\u2019s disease. Faseb J. 2005;19(6):533\u201342.","journal-title":"Faseb J"},{"issue":"11","key":"879_CR188","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.neurobiolaging.2007.04.006","volume":"29","author":"X Su","year":"2008","unstructured":"Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson\u2019s disease. Neurobiol Aging. 2008;29(11):1690\u2013701.","journal-title":"Neurobiol Aging"},{"issue":"1","key":"879_CR189","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12974-022-02496-w","volume":"19","author":"A Heidari","year":"2022","unstructured":"Heidari A, Yazdanpanah N, Rezaei N. The role of Toll-like receptors and neuroinflammation in Parkinson\u2019s disease. J Neuroinflammation. 2022;19(1):135.","journal-title":"J Neuroinflammation"},{"issue":"10","key":"879_CR190","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jalz.2015.05.011","volume":"11","author":"MW Lutz","year":"2015","unstructured":"Lutz MW, Saul R, Linnertz C, Glenn OC, Roses AD, Chiba-Falek O. A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer\u2019s disease and affects SNCA expression. Alzheimers Dement. 2015;11(10):1133\u201343.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"879_CR191","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1074\/jbc.M610544200","volume":"282","author":"RG Boot","year":"2007","unstructured":"Boot RG, Verhoek M, Donker-Koopman W, Strijland A, van Marle J, Overkleeft HS, et al. Identification of the non-lysosomal glucosylceramidase as beta-glucosidase 2. J Biol Chem. 2007;282(2):1305\u201312.","journal-title":"J Biol Chem"},{"issue":"3","key":"879_CR192","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/mds.24045","volume":"27","author":"N Set\u00f3-Salvia","year":"2012","unstructured":"Set\u00f3-Salvia N, Pagonabarraga J, Houlden H, Pascual-Sedano B, Dols-Icardo O, Tucci A, et al. Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson\u2019s disease course. Mov Disord. 2012;27(3):393\u20139.","journal-title":"Mov Disord"},{"issue":"23","key":"879_CR193","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1093\/hmg\/ddu334","volume":"23","author":"J Bras","year":"2014","unstructured":"Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014;23(23):6139\u201346.","journal-title":"Hum Mol Genet"},{"issue":"17","key":"879_CR194","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med. 2009;361(17):1651\u201361.","journal-title":"N Engl J Med"},{"issue":"6","key":"879_CR195","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","volume":"70","author":"MA Nalls","year":"2013","unstructured":"Nalls MA, Duran R, Lopez G, Kurzawa-Akanbi M, McKeith IG, Chinnery PF, et al. A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol. 2013;70(6):727\u201335.","journal-title":"JAMA Neurol"},{"issue":"12","key":"879_CR196","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.wnl.0000276989.17578.02","volume":"69","author":"LN Clark","year":"2007","unstructured":"Clark LN, Ross BM, Wang Y, Mejia-Santana H, Harris J, Louis ED, et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology. 2007;69(12):1270\u20137.","journal-title":"Neurology"},{"issue":"1","key":"879_CR197","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40035-020-00226-x","volume":"10","author":"T Behl","year":"2021","unstructured":"Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, et al. Cross-talks among GBA mutations, glucocerebrosidase, and \u03b1-synuclein in GBA-associated Parkinson\u2019s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener. 2021;10(1):4.","journal-title":"Transl Neurodegener"},{"issue":"3","key":"879_CR198","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","volume":"42","author":"L Alvarez-Erviti","year":"2011","unstructured":"Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42(3):360\u20137.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"879_CR199","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1038\/emm.2014.128","volume":"47","author":"EJ Bae","year":"2015","unstructured":"Bae EJ, Yang NY, Lee C, Lee HJ, Kim S, Sardi SP, et al. Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and \u03b1-synuclein aggregation. Exp Mol Med. 2015;47(3):e153.","journal-title":"Exp Mol Med"},{"key":"879_CR200","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pneurobio.2014.12.001","volume":"125","author":"SP Sardi","year":"2015","unstructured":"Sardi SP, Cheng SH, Shihabuddin LS. Gaucher-related synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle. Prog Neurobiol. 2015;125:47\u201362.","journal-title":"Prog Neurobiol"},{"issue":"5785","key":"879_CR201","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1126\/science.1129462","volume":"313","author":"AA Cooper","year":"2006","unstructured":"Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in parkinson\u2019s models. Science. 2006;313(5785):324\u20138.","journal-title":"Science"},{"issue":"7","key":"879_CR202","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.1520335113","volume":"113","author":"JR Mazzulli","year":"2016","unstructured":"Mazzulli JR, Zunke F, Isacson O, Studer L, Krainc D. \u03b1-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proc Natl Acad Sci U S A. 2016;113(7):1931\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"879_CR203","doi-asserted-by":"publisher","first-page":"e3001287","DOI":"10.1371\/journal.pbio.3001287","volume":"19","author":"A Dilsizoglu Senol","year":"2021","unstructured":"Dilsizoglu Senol A, Samarani M, Syan S, Guardia CM, Nonaka T, Liv N, et al. \u03b1-Synuclein fibrils subvert lysosome structure and function for the propagation of protein misfolding between cells through tunneling nanotubes. PLoS Biol. 2021;19(7):e3001287.","journal-title":"PLoS Biol"},{"issue":"1","key":"879_CR204","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146(1):37\u201352.","journal-title":"Cell"},{"key":"879_CR205","doi-asserted-by":"crossref","unstructured":"Smith L, Schapira AHV. GBA variants and Parkinson disease: mechanisms and treatments. Cells. 2022;11(8).","DOI":"10.3390\/cells11081261"},{"issue":"12","key":"879_CR206","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/humu.23611","volume":"39","author":"BA Davidson","year":"2018","unstructured":"Davidson BA, Hassan S, Garcia EJ, Tayebi N, Sidransky E. Exploring genetic modifiers of gaucher disease: the next horizon. Hum Mutat. 2018;39(12):1739\u201351.","journal-title":"Hum Mutat"},{"issue":"40","key":"879_CR207","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes \u03b1-Synuclein pathology in mutant GBA-Associated Parkinson\u2019s disease. J Neurosci. 2017;37(40):9617\u201331.","journal-title":"J Neurosci"},{"issue":"1","key":"879_CR208","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.neuron.2017.12.012","volume":"97","author":"F Zunke","year":"2018","unstructured":"Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of \u03b1-Synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97(1):92\u2013e107110.","journal-title":"Neuron"},{"issue":"5","key":"879_CR209","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.neuron.2019.12.004","volume":"105","author":"MX Henderson","year":"2020","unstructured":"Henderson MX, Sedor S, McGeary I, Cornblath EJ, Peng C, Riddle DM, et al. Glucocerebrosidase activity modulates neuronal susceptibility to pathological \u03b1-Synuclein insult. Neuron. 2020;105(5):822\u2013e836827.","journal-title":"Neuron"},{"issue":"1","key":"879_CR210","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"TF Outeiro","year":"2019","unstructured":"Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14(1):5.","journal-title":"Mol Neurodegener"},{"key":"879_CR211","doi-asserted-by":"publisher","first-page":"101822","DOI":"10.1016\/j.pneurobio.2020.101822","volume":"192","author":"L Chouliaras","year":"2020","unstructured":"Chouliaras L, Kumar GS, Thomas AJ, Lunnon K, Chinnery PF, O\u2019Brien JT. Epigenetic regulation in the pathophysiology of Lewy body dementia. Prog Neurobiol. 2020;192:101822.","journal-title":"Prog Neurobiol"},{"issue":"3","key":"879_CR212","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41588-021-00785-3","volume":"53","author":"R Chia","year":"2021","unstructured":"Chia R, Sabir MS, Bandres-Ciga S, Saez-Atienzar S, Reynolds RH, Gustavsson E, et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021;53(3):294\u2013303.","journal-title":"Nat Genet"},{"issue":"3","key":"879_CR213","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jalz.2017.09.014","volume":"14","author":"TJ Ferman","year":"2018","unstructured":"Ferman TJ, Aoki N, Crook JE, Murray ME, Graff-Radford NR, van Gerpen JA, et al. The limbic and neocortical contribution of \u03b1-synuclein, tau, and amyloid \u03b2 to disease duration in dementia with Lewy bodies. Alzheimers Dement. 2018;14(3):330\u20139.","journal-title":"Alzheimers Dement"},{"key":"879_CR214","doi-asserted-by":"crossref","unstructured":"Karanth S, Nelson P, Katsumata Y, Kryscio R, Schmitt F, Fardo D et al. Prevalence and clinical phenotype of quadruple misfolded proteins in older adults. JAMA Neurol. 2020;77.","DOI":"10.1001\/jamaneurol.2020.1741"},{"issue":"21","key":"879_CR215","doi-asserted-by":"publisher","first-page":"12245","DOI":"10.1073\/pnas.211412398","volume":"98","author":"E Masliah","year":"2001","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, et al. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a Transgenic mouse model linking Alzheimer\u2019s disease and Parkinson\u2019s disease. Proc Natl Acad Sci U S A. 2001;98(21):12245\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"879_CR216","doi-asserted-by":"publisher","first-page":"e3135","DOI":"10.1371\/journal.pone.0003135","volume":"3","author":"IF Tsigelny","year":"2008","unstructured":"Tsigelny IF, Crews L, Desplats P, Shaked GM, Sharikov Y, Mizuno H, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer\u2019s and Parkinson\u2019s diseases. PLoS ONE. 2008;3(9):e3135.","journal-title":"PLoS ONE"},{"issue":"30","key":"879_CR217","doi-asserted-by":"publisher","first-page":"7971","DOI":"10.1523\/JNEUROSCI.0775-16.2016","volume":"36","author":"B Spencer","year":"2016","unstructured":"Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, et al. Reducing endogenous \u03b1-Synuclein mitigates the degeneration of selective neuronal populations in an Alzheimer\u2019s disease Transgenic mouse model. J Neurosci. 2016;36(30):7971\u201384.","journal-title":"J Neurosci"},{"issue":"5","key":"879_CR218","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/j.1471-4159.2012.07847.x","volume":"122","author":"K Ono","year":"2012","unstructured":"Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid \u03b2-protein and \u03b1-synuclein. J Neurochem. 2012;122(5):883\u201390.","journal-title":"J Neurochem"},{"issue":"30","key":"879_CR219","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1073\/pnas.1700239114","volume":"114","author":"S Chia","year":"2017","unstructured":"Chia S, Flagmeier P, Habchi J, Lattanzi V, Linse S, Dobson CM, et al. Monomeric and fibrillar \u03b1-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of A\u03b242 aggregates. Proc Natl Acad Sci U S A. 2017;114(30):8005\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"879_CR220","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2019.10.010","volume":"105","author":"F Bassil","year":"2020","unstructured":"Bassil F, Brown HJ, Pattabhiraman S, Iwasyk JE, Maghames CM, Meymand ES, et al. Amyloid-Beta (A\u03b2) plaques promote seeding and spreading of Alpha-Synuclein and Tau in a mouse model of Lewy body disorders with A\u03b2 pathology. Neuron. 2020;105(2):260\u2013e275266.","journal-title":"Neuron"},{"issue":"6","key":"879_CR221","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","volume":"27","author":"ML Kramer","year":"2007","unstructured":"Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27(6):1405\u201310.","journal-title":"J Neurosci"},{"key":"879_CR222","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fnins.2020.00286","volume":"14","author":"M Iba","year":"2020","unstructured":"Iba M, Kim C, Florio J, Mante M, Adame A, Rockenstein E, et al. Role of alterations in protein kinase p38\u03b3 in the pathogenesis of the synaptic pathology in dementia with Lewy bodies and \u03b1-Synuclein Transgenic models. Front Neurosci. 2020;14:286.","journal-title":"Front Neurosci"},{"key":"879_CR223","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1750-1326-5-55","volume":"5","author":"C Bate","year":"2010","unstructured":"Bate C, Gentleman S, Williams A. \u03b1-synuclein induced synapse damage is enhanced by amyloid-\u03b21\u201342. Mol Neurodegener. 2010;5:55.","journal-title":"Mol Neurodegener"},{"key":"879_CR224","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.expneurol.2015.10.009","volume":"275","author":"CL Lin","year":"2016","unstructured":"Lin CL, Cheng YS, Li HH, Chiu PY, Chang YT, Ho YJ, et al. Amyloid-\u03b2 suppresses AMP-activated protein kinase (AMPK) signaling and contributes to \u03b1-synuclein-induced cytotoxicity. Exp Neurol. 2016;275:84\u201398.","journal-title":"Exp Neurol"},{"issue":"1","key":"879_CR225","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/cns.12772","volume":"24","author":"CC Chang","year":"2018","unstructured":"Chang CC, Li HH, Chang YT, Ho YJ, Hsieh LJ, Chiu PY, et al. A\u03b2 exacerbates \u03b1-synuclein-induced neurotoxicity through impaired insulin signaling in \u03b1-synuclein-overexpressed human SK-N-MC neuronal cells. CNS Neurosci Ther. 2018;24(1):47\u201357.","journal-title":"CNS Neurosci Ther"},{"key":"879_CR226","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1750-1326-9-18","volume":"9","author":"CR Overk","year":"2014","unstructured":"Overk CR, Cartier A, Shaked G, Rockenstein E, Ubhi K, Spencer B, et al. Hippocampal neuronal cells that accumulate \u03b1-synuclein fragments are more vulnerable to A\u03b2 oligomer toxicity via mGluR5\u2013implications for dementia with Lewy bodies. Mol Neurodegener. 2014;9:18.","journal-title":"Mol Neurodegener"},{"key":"879_CR227","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.neurobiolaging.2020.11.006","volume":"101","author":"E Mak","year":"2021","unstructured":"Mak E, Nicastro N, Malpetti M, Savulich G, Surendranathan A, Holland N, et al. Imaging Tau burden in dementia with Lewy bodies using [(18)F]-AV1451 positron emission tomography. Neurobiol Aging. 2021;101:172\u201380.","journal-title":"Neurobiol Aging"},{"issue":"2","key":"879_CR228","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s004010050002","volume":"100","author":"K Arima","year":"2000","unstructured":"Arima K, Mizutani T, Alim MA, Tonozuka-Uehara H, Izumiyama Y, Hirai S, et al. NACP\/alpha-synuclein and Tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. Acta Neuropathol. 2000;100(2):115\u201321.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"879_CR229","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","volume":"62","author":"T Ishizawa","year":"2003","unstructured":"Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of Tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol. 2003;62(4):389\u201397.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"879_CR230","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00401-023-02657-y","volume":"147","author":"BL van der Gaag","year":"2024","unstructured":"van der Gaag BL, Deshayes NAC, Breve JJP, Bol J, Jonker AJ, Hoozemans JJM, et al. Distinct Tau and alpha-synuclein molecular signatures in Alzheimer\u2019s disease with and without Lewy bodies and Parkinson\u2019s disease with dementia. Acta Neuropathol. 2024;147(1):14.","journal-title":"Acta Neuropathol"},{"issue":"36","key":"879_CR231","doi-asserted-by":"publisher","first-page":"25481","DOI":"10.1074\/jbc.274.36.25481","volume":"274","author":"PH Jensen","year":"1999","unstructured":"Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R. alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed Tau phosphorylation of Serine residues 262 and 356. J Biol Chem. 1999;274(36):25481\u20139.","journal-title":"J Biol Chem"},{"issue":"3","key":"879_CR232","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.nbd.2007.01.014","volume":"26","author":"A Esposito","year":"2007","unstructured":"Esposito A, Dohm CP, Kermer P, B\u00e4hr M, Wouters FS. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein Tau and associate with the actin cytoskeleton. Neurobiol Dis. 2007;26(3):521\u201331.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"879_CR233","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bbrc.2008.01.140","volume":"368","author":"HJ Koo","year":"2008","unstructured":"Koo HJ, Lee HJ, Im H. Sequence determinants regulating fibrillation of human alpha-synuclein. Biochem Biophys Res Commun. 2008;368(3):772\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"879_CR234","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.yexcr.2005.04.021","volume":"308","author":"L Benussi","year":"2005","unstructured":"Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, Signorini S, et al. Interaction between Tau and alpha-synuclein proteins is impaired in the presence of P301L Tau mutation. Exp Cell Res. 2005;308(1):78\u201384.","journal-title":"Exp Cell Res"},{"issue":"9","key":"879_CR235","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1460-9568.2011.07660.x","volume":"33","author":"T Haggerty","year":"2011","unstructured":"Haggerty T, Credle J, Rodriguez O, Wills J, Oaks AW, Masliah E, et al. Hyperphosphorylated Tau in an \u03b1-synuclein-overexpressing Transgenic model of Parkinson\u2019s disease. Eur J Neurosci. 2011;33(9):1598\u2013610.","journal-title":"Eur J Neurosci"},{"issue":"11","key":"879_CR236","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1093\/hmg\/ddu011","volume":"23","author":"B Roy","year":"2014","unstructured":"Roy B, Jackson GR. Interactions between Tau and \u03b1-synuclein augment neurotoxicity in a drosophila model of Parkinson\u2019s disease. Hum Mol Genet. 2014;23(11):3008\u201323.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"879_CR237","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00401-019-02032-w","volume":"138","author":"B Singh","year":"2019","unstructured":"Singh B, Covelo A, Martell-Mart\u00ednez H, Nanclares C, Sherman MA, Okematti E, et al. Tau is required for progressive synaptic and memory deficits in a Transgenic mouse model of \u03b1-synucleinopathy. Acta Neuropathol. 2019;138(4):551\u201374.","journal-title":"Acta Neuropathol"},{"issue":"21","key":"879_CR238","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0490-10.2010","volume":"30","author":"LK Clinton","year":"2010","unstructured":"Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci. 2010;30(21):7281\u20139.","journal-title":"J Neurosci"},{"issue":"1","key":"879_CR239","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00018-024-05383-0","volume":"81","author":"R Li","year":"2024","unstructured":"Li R, Huang X, Shen L, Zhang T, Liu N, Hou X, et al. Novel C. elegans models of Lewy body disease reveal pathological protein interactions and widespread MiRNA dysregulation. Cell Mol Life Sci. 2024;81(1):377.","journal-title":"Cell Mol Life Sci"},{"key":"879_CR240","doi-asserted-by":"crossref","unstructured":"Noguchi-Shinohara M, Ono K. The mechanisms of the roles of \u03b1-Synuclein, Amyloid-\u03b2, and Tau protein in the Lewy body diseases: pathogenesis, early detection, and therapeutics. Int J Mol Sci. 2023;24(12).","DOI":"10.3390\/ijms241210215"},{"issue":"2","key":"879_CR241","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00401-016-1558-9","volume":"132","author":"KR Sadleir","year":"2016","unstructured":"Sadleir KR, Kandalepas PC, Buggia-Pr\u00e9vot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased A\u03b2 generation in Alzheimer\u2019s disease. Acta Neuropathol. 2016;132(2):235\u201356.","journal-title":"Acta Neuropathol"},{"issue":"46","key":"879_CR242","doi-asserted-by":"publisher","first-page":"7267","DOI":"10.1039\/C9TB01871A","volume":"7","author":"B Ren","year":"2019","unstructured":"Ren B, Zhang Y, Zhang M, Liu Y, Zhang D, Gong X, et al. Fundamentals of cross-seeding of amyloid proteins: an introduction. J Mater Chem B. 2019;7(46):7267\u201382.","journal-title":"J Mater Chem B"},{"issue":"2","key":"879_CR243","doi-asserted-by":"publisher","first-page":"234","DOI":"10.7150\/ijbs.7.234","volume":"7","author":"T Tian","year":"2011","unstructured":"Tian T, Huang C, Tong J, Yang M, Zhou H, Xia XG. TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in Transgenic mice. Int J Biol Sci. 2011;7(2):234\u201343.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"879_CR244","doi-asserted-by":"publisher","first-page":"165876","DOI":"10.1016\/j.bbadis.2020.165876","volume":"1866","author":"L Shen","year":"2020","unstructured":"Shen L, Wang C, Chen L, Leung KL, Lo E, Lakso M, et al. TDP-1\/TDP-43 potentiates human \u03b1-Synuclein (HASN) neurodegeneration in caenorhabditis elegans. Biochim Biophys Acta Mol Basis Dis. 2020;1866(10):165876.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"5619","key":"879_CR245","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1082324","volume":"300","author":"BI Giasson","year":"2003","unstructured":"Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of Tau and alpha-synuclein. Science. 2003;300(5619):636\u201340.","journal-title":"Science"},{"issue":"6","key":"879_CR246","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1111\/j.1742-4658.2005.04571.x","volume":"272","author":"P Zabrocki","year":"2005","unstructured":"Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, Wera S, et al. Characterization of alpha-synuclein aggregation and synergistic toxicity with protein Tau in yeast. Febs J. 2005;272(6):1386\u2013400.","journal-title":"Febs J"},{"issue":"2","key":"879_CR247","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.expneurol.2004.07.016","volume":"192","author":"M Frasier","year":"2005","unstructured":"Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, Haas C, et al. Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol. 2005;192(2):274\u201387.","journal-title":"Exp Neurol"},{"issue":"13","key":"879_CR248","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1096\/fj.06-6092com","volume":"20","author":"T Duka","year":"2006","unstructured":"Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, et al. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. Faseb J. 2006;20(13):2302\u201312.","journal-title":"Faseb J"},{"issue":"9","key":"879_CR249","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1096\/fj.08-120410","volume":"23","author":"T Duka","year":"2009","unstructured":"Duka T, Duka V, Joyce JN, Sidhu A. Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson\u2019s disease models. Faseb J. 2009;23(9):2820\u201330.","journal-title":"Faseb J"},{"issue":"21","key":"879_CR250","doi-asserted-by":"publisher","first-page":"7604","DOI":"10.1523\/JNEUROSCI.0297-11.2011","volume":"31","author":"EA Waxman","year":"2011","unstructured":"Waxman EA, Giasson BI. Induction of intracellular Tau aggregation is promoted by \u03b1-synuclein seeds and provides novel insights into the hyperphosphorylation of Tau. J Neurosci. 2011;31(21):7604\u201318.","journal-title":"J Neurosci"},{"issue":"10","key":"879_CR251","doi-asserted-by":"publisher","first-page":"e26609","DOI":"10.1371\/journal.pone.0026609","volume":"6","author":"N Badiola","year":"2011","unstructured":"Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Gon\u00e7alves SA, Pera M, et al. Tau enhances \u03b1-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS ONE. 2011;6(10):e26609.","journal-title":"PLoS ONE"},{"issue":"7","key":"879_CR252","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1074\/jbc.M110.178905","volume":"286","author":"HY Qureshi","year":"2011","unstructured":"Qureshi HY, Paudel HK. Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem. 2011;286(7):5055\u201368.","journal-title":"J Biol Chem"},{"issue":"3","key":"879_CR253","doi-asserted-by":"publisher","first-page":"e17953","DOI":"10.1371\/journal.pone.0017953","volume":"6","author":"J Wills","year":"2011","unstructured":"Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, Sidhu A. Tauopathic changes in the striatum of A53T \u03b1-synuclein mutant mouse model of Parkinson\u2019s disease. PLoS ONE. 2011;6(3):e17953.","journal-title":"PLoS ONE"},{"key":"879_CR254","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1471-2202-12-79","volume":"12","author":"T Kaul","year":"2011","unstructured":"Kaul T, Credle J, Haggerty T, Oaks AW, Masliah E, Sidhu A. Region-specific tauopathy and synucleinopathy in brain of the alpha-synuclein overexpressing mouse model of Parkinson\u2019s disease. BMC Neurosci. 2011;12:79.","journal-title":"BMC Neurosci"},{"issue":"40","key":"879_CR255","doi-asserted-by":"publisher","first-page":"35104","DOI":"10.1074\/jbc.M111.247965","volume":"286","author":"KL Emmer","year":"2011","unstructured":"Emmer KL, Waxman EA, Covy JP, Giasson BI. E46K human alpha-synuclein Transgenic mice develop Lewy-like and Tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem. 2011;286(40):35104\u201318.","journal-title":"J Biol Chem"},{"issue":"1","key":"879_CR256","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cell.2013.05.057","volume":"154","author":"JL Guo","year":"2013","unstructured":"Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, et al. Distinct \u03b1-synuclein strains differentially promote Tau inclusions in neurons. Cell. 2013;154(1):103\u201317.","journal-title":"Cell"},{"issue":"2","key":"879_CR257","doi-asserted-by":"publisher","first-page":"e55848","DOI":"10.1371\/journal.pone.0055848","volume":"8","author":"G Ciaccioli","year":"2013","unstructured":"Ciaccioli G, Martins A, Rodrigues C, Vieira H, Calado P. A powerful yeast model to investigate the synergistic interaction of \u03b1-synuclein and Tau in neurodegeneration. PLoS ONE. 2013;8(2):e55848.","journal-title":"PLoS ONE"},{"issue":"1","key":"879_CR258","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12640-012-9330-y","volume":"23","author":"S Majd","year":"2013","unstructured":"Majd S, Chegini F, Chataway T, Zhou XF, Gai W. Reciprocal induction between \u03b1-synuclein and \u03b2-amyloid in adult rat neurons. Neurotox Res. 2013;23(1):69\u201378.","journal-title":"Neurotox Res"},{"issue":"4","key":"879_CR259","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s11064-013-0982-7","volume":"38","author":"R Resende","year":"2013","unstructured":"Resende R, Marques SC, Ferreiro E, Sim\u00f5es I, Oliveira CR, Pereira CM. Effect of \u03b1-synuclein on amyloid \u03b2-induced toxicity: relevance to Lewy body variant of Alzheimer disease. Neurochem Res. 2013;38(4):797\u2013806.","journal-title":"Neurochem Res"},{"issue":"5\u20138","key":"879_CR260","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13195-014-0077-y","volume":"6","author":"M Swirski","year":"2014","unstructured":"Swirski M, Miners JS, de Silva R, Lashley T, Ling H, Holton J, et al. Evaluating the relationship between amyloid-\u03b2 and \u03b1-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson\u2019s disease. Alzheimers Res Ther. 2014;6(5\u20138):77.","journal-title":"Alzheimers Res Ther"},{"issue":"7","key":"879_CR261","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.biopsych.2017.12.018","volume":"84","author":"DL Castillo-Carranza","year":"2018","unstructured":"Castillo-Carranza DL, Guerrero-Mu\u00f1oz MJ, Sengupta U, Gerson JE, Kayed R. \u03b1-Synuclein oligomers induce a unique toxic Tau strain. Biol Psychiatry. 2018;84(7):499\u2013508.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"879_CR262","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13024-018-0245-9","volume":"13","author":"JE Gerson","year":"2018","unstructured":"Gerson JE, Farmer KM, Henson N, Castillo-Carranza DL, Carretero Murillo M, Sengupta U, et al. Tau oligomers mediate \u03b1-synuclein toxicity and can be targeted by immunotherapy. Mol Neurodegener. 2018;13(1):13.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"879_CR263","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jalz.2019.02.002","volume":"15","author":"M Mandler","year":"2019","unstructured":"Mandler M, Rockenstein E, Overk C, Mante M, Florio J, Adame A, et al. Effects of single and combined immunotherapy approach targeting amyloid \u03b2 protein and \u03b1-synuclein in a dementia with Lewy bodies-like model. Alzheimers Dement. 2019;15(9):1133\u201348.","journal-title":"Alzheimers Dement"},{"key":"879_CR264","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fneur.2020.00563","volume":"11","author":"ST Peters","year":"2020","unstructured":"Peters ST, Fahrenkopf A, Choquette JM, Vermilyea SC, Lee MK, Vossel K. Ablating Tau reduces hyperexcitability and moderates electroencephalographic slowing in Transgenic mice expressing A53T human \u03b1-Synuclein. Front Neurol. 2020;11:563.","journal-title":"Front Neurol"},{"issue":"6","key":"879_CR265","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s12035-020-01913-6","volume":"57","author":"U Sengupta","year":"2020","unstructured":"Sengupta U, Puangmalai N, Bhatt N, Garcia S, Zhao Y, Kayed R. Polymorphic \u03b1-Synuclein strains modified by dopamine and docosahexaenoic acid interact differentially with Tau protein. Mol Neurobiol. 2020;57(6):2741\u201365.","journal-title":"Mol Neurobiol"},{"issue":"1","key":"879_CR266","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40478-020-00969-8","volume":"8","author":"Y Takaichi","year":"2020","unstructured":"Takaichi Y, Chambers JK, Inoue H, Ano Y, Takashima A, Nakayama H, et al. Phosphorylation and oligomerization of \u03b1-synuclein associated with GSK-3\u03b2 activation in the rTg4510 mouse model of tauopathy. Acta Neuropathol Commun. 2020;8(1):86.","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"879_CR267","doi-asserted-by":"publisher","first-page":"fcaa090","DOI":"10.1093\/braincomms\/fcaa090","volume":"2","author":"T Williams","year":"2020","unstructured":"Williams T, Sorrentino Z, Weinrich M, Giasson BI, Chakrabarty P. Differential cross-seeding properties of Tau and \u03b1-synuclein in mouse models of Tauopathy and synucleinopathy. Brain Commun. 2020;2(2):fcaa090.","journal-title":"Brain Commun"},{"issue":"1","key":"879_CR268","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-021-00486-9","volume":"16","author":"GM Lloyd","year":"2021","unstructured":"Lloyd GM, Dhillon JS, Gorion KM, Riffe C, Fromholt SE, Xia Y, et al. Collusion of \u03b1-Synuclein and A\u03b2 aggravating co-morbidities in a novel prion-type mouse model. Mol Neurodegener. 2021;16(1):63.","journal-title":"Mol Neurodegener"},{"issue":"10","key":"879_CR269","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/brain\/awac171","volume":"145","author":"L Pan","year":"2022","unstructured":"Pan L, Li C, Meng L, Tian Y, He M, Yuan X, et al. Tau accelerates \u03b1-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain. 2022;145(10):3454\u201371.","journal-title":"Brain"},{"issue":"1","key":"879_CR270","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40035-022-00309-x","volume":"11","author":"SC Vermilyea","year":"2022","unstructured":"Vermilyea SC, Christensen A, Meints J, Singh B, Martell-Mart\u00ednez H, Karim MR, et al. Loss of Tau expression attenuates neurodegeneration associated with \u03b1-synucleinopathy. Transl Neurodegener. 2022;11(1):34.","journal-title":"Transl Neurodegener"},{"issue":"3","key":"879_CR271","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41419-019-1404-9","volume":"10","author":"Y Xia","year":"2019","unstructured":"Xia Y, Zhang G, Han C, Ma K, Guo X, Wan F, et al. Microglia as modulators of Exosomal alpha-synuclein transmission. Cell Death Dis. 2019;10(3):174.","journal-title":"Cell Death Dis"},{"issue":"1","key":"879_CR272","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1750-3639.2011.00545.x","volume":"22","author":"CL Kragh","year":"2012","unstructured":"Kragh CL, Ubhi K, Wyss-Coray T, Masliah E. Autophagy in dementias. Brain Pathol. 2012;22(1):99\u2013109.","journal-title":"Brain Pathol"},{"issue":"10","key":"879_CR273","doi-asserted-by":"publisher","first-page":"166953","DOI":"10.1016\/j.jmb.2021.166953","volume":"433","author":"S Dhakal","year":"2021","unstructured":"Dhakal S, Wyant CE, George HE, Morgan SE, Rangachari V. Prion-like C-Terminal domain of TDP-43 and \u03b1-Synuclein interact synergistically to generate neurotoxic hybrid fibrils. J Mol Biol. 2021;433(10):166953.","journal-title":"J Mol Biol"},{"issue":"1","key":"879_CR274","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/s42003-023-05608-1","volume":"6","author":"S Dhakal","year":"2023","unstructured":"Dhakal S, Mondal M, Mirzazadeh A, Banerjee S, Ghosh A, Rangachari V. \u03b1-Synuclein emulsifies TDP-43 prion-like domain-RNA liquid droplets to promote heterotypic amyloid fibrils. Commun Biol. 2023;6(1):1227.","journal-title":"Commun Biol"},{"issue":"Suppl 1","key":"879_CR275","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.expneurol.2004.08.021","volume":"191","author":"R Betarbet","year":"2005","unstructured":"Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson\u2019s diseases. Exp Neurol. 2005;191(Suppl 1):S17\u201327.","journal-title":"Exp Neurol"},{"key":"879_CR276","doi-asserted-by":"crossref","unstructured":"Nixon RA, Rubinsztein DC. Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024.","DOI":"10.1038\/s41580-024-00757-5"},{"issue":"3\u20134","key":"879_CR277","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000486546","volume":"45","author":"R Knight","year":"2018","unstructured":"Knight R, Khondoker M, Magill N, Stewart R, Landau S. A systematic review and Meta-Analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord. 2018;45(3\u20134):131\u201351.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"879_CR278","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/gps.4109","volume":"30","author":"KA Wesnes","year":"2015","unstructured":"Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson\u2019s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30(1):46\u201354.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"15","key":"879_CR279","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/mds.22322","volume":"23","author":"JG Goldman","year":"2008","unstructured":"Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248\u201350.","journal-title":"Mov Disord"},{"issue":"11","key":"879_CR280","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/mds.27488","volume":"33","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Guskey MT, Norton JC, Coate B, Vizcarra JA, Ballard C, et al. Pimavanserin for Parkinson\u2019s disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord. 2018;33(11):1769\u201376.","journal-title":"Mov Disord"},{"issue":"3","key":"879_CR281","first-page":"Cd003672","volume":"2003","author":"R Wild","year":"2003","unstructured":"Wild R, Pettit T, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database Syst Rev. 2003;2003(3):Cd003672.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9247","key":"879_CR282","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(00)03399-7","volume":"356","author":"I McKeith","year":"2000","unstructured":"McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of Rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031\u20136.","journal-title":"Lancet"},{"issue":"2","key":"879_CR283","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1440-1819.2006.01485.x","volume":"60","author":"S Mori","year":"2006","unstructured":"Mori S, Mori E, Iseki E, Kosaka K. Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study. Psychiatry Clin Neurosci. 2006;60(2):190\u20135.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"879_CR284","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/mds.22495","volume":"24","author":"I Leroi","year":"2009","unstructured":"Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A. Randomized controlled trial of memantine in dementia associated with Parkinson\u2019s disease. Mov Disord. 2009;24(8):1217\u201321.","journal-title":"Mov Disord"},{"issue":"1","key":"879_CR285","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.coph.2005.09.007","volume":"6","author":"JW Johnson","year":"2006","unstructured":"Johnson JW, Kotermanski SE. Mechanism of action of memantine. Curr Opin Pharmacol. 2006;6(1):61\u20137.","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"879_CR286","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","volume":"53","author":"CG Parsons","year":"2007","unstructured":"Parsons CG, St\u00f6ffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2013too little activation is bad, too much is even worse. Neuropharmacology. 2007;53(6):699\u2013723.","journal-title":"Neuropharmacology"},{"issue":"1","key":"879_CR287","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s002210000446","volume":"134","author":"LB Willard","year":"2000","unstructured":"Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 Inhibition. Exp Brain Res. 2000;134(1):58\u201365.","journal-title":"Exp Brain Res"},{"issue":"10","key":"879_CR288","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1111\/j.1460-9568.2008.06498.x","volume":"28","author":"MS Song","year":"2008","unstructured":"Song MS, Rauw G, Baker GB, Kar S. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating Tau phosphorylation. Eur J Neurosci. 2008;28(10):1989\u20132002.","journal-title":"Eur J Neurosci"},{"issue":"1","key":"879_CR289","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12974-019-1695-x","volume":"17","author":"LL Qiu","year":"2020","unstructured":"Qiu LL, Pan W, Luo D, Zhang GF, Zhou ZQ, Sun XY, et al. Dysregulation of bdnf\/trkb signaling mediated by NMDAR\/Ca(2+)\/calpain might contribute to postoperative cognitive dysfunction in aging mice. J Neuroinflammation. 2020;17(1):23.","journal-title":"J Neuroinflammation"},{"issue":"14","key":"879_CR290","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ. Memantine in moderate-to-severe Alzheimer\u2019s disease. N Engl J Med. 2003;348(14):1333\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"879_CR291","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ibra.12098","volume":"9","author":"BC Tang","year":"2023","unstructured":"Tang BC, Wang YT, Ren J. Basic information about memantine and its treatment of Alzheimer\u2019s disease and other clinical applications. Ibrain. 2023;9(3):340\u20138.","journal-title":"Ibrain"},{"issue":"10","key":"879_CR292","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S1474-4422(10)70194-0","volume":"9","author":"M Emre","year":"2010","unstructured":"Emre M, Tsolaki M, Bonuccelli U, Dest\u00e9e A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson\u2019s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969\u201377.","journal-title":"Lancet Neurol"},{"issue":"2","key":"879_CR293","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/mdc3.12264","volume":"3","author":"L Brennan","year":"2016","unstructured":"Brennan L, Pantelyat A, Duda JE, Morley JF, Weintraub D, Wilkinson JR, et al. Memantine and cognition in Parkinson\u2019s disease dementia\/dementia with Lewy bodies: A Meta-Analysis. Mov Disord Clin Pract. 2016;3(2):161\u20137.","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"879_CR294","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/0269881116680924","volume":"31","author":"JT O\u2019Brien","year":"2017","unstructured":"O\u2019Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British association for psychopharmacology. J Psychopharmacol. 2017;31(2):147\u201368.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"879_CR295","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/psyg.12089","volume":"15","author":"K Ukai","year":"2015","unstructured":"Ukai K, Fujishiro H, Iritani S, Ozaki N. Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies. Psychogeriatrics. 2015;15(2):133\u20137.","journal-title":"Psychogeriatrics"},{"issue":"2","key":"879_CR296","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1017\/S104161020100758X","volume":"13","author":"J Grace","year":"2001","unstructured":"Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, et al. Long-Term use of Rivastigmine in patients with dementia with Lewy bodies: an open-label trial. Int Psychogeriatr. 2001;13(2):199\u2013205.","journal-title":"Int Psychogeriatr"},{"issue":"Suppl 1","key":"879_CR297","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000074681","volume":"17","author":"KR Edwards","year":"2004","unstructured":"Edwards KR, Hershey L, Wray L, Bednarczyk EM, Lichter D, Farlow M, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 12-week interim analysis. Dement Geriatr Cogn Disord. 2004;17(Suppl 1):40\u20138.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"879_CR298","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/mds.20051","volume":"19","author":"HH Fernandez","year":"2004","unstructured":"Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord. 2004;19(7):831\u20133.","journal-title":"Mov Disord"},{"issue":"5","key":"879_CR299","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, Dest\u00e9e A, P\u00e9r\u00e9 JJ, Senard JM, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75(5):689\u201395.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"879_CR300","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","volume":"76","author":"A Chang","year":"2016","unstructured":"Chang A, Fox SH. Psychosis in Parkinson\u2019s disease: epidemiology, pathophysiology, and management. Drugs. 2016;76(11):1093\u2013118.","journal-title":"Drugs"},{"key":"879_CR301","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.parkreldis.2020.05.026","volume":"75","author":"K Kyle","year":"2020","unstructured":"Kyle K, Bronstein JM. Treatment of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies: A review. Parkinsonism Relat Disord. 2020;75:55\u201362.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"879_CR302","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJM199903113401003","volume":"340","author":"PS Group","year":"1999","unstructured":"Group PS. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340(10):757\u201363.","journal-title":"N Engl J Med"},{"issue":"1","key":"879_CR303","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mdc3.12383","volume":"4","author":"MJ Armstrong","year":"2017","unstructured":"Armstrong MJ, Weintraub D. The case for antipsychotics in dementia with Lewy bodies. Mov Disord Clin Pract. 2017;4(1):32\u20135.","journal-title":"Mov Disord Clin Pract"},{"key":"879_CR304","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fphar.2020.00087","volume":"11","author":"I Yunusa","year":"2020","unstructured":"Yunusa I, El Helou ML, Alsahali S. Pimavanserin: A novel antipsychotic with potentials to address an unmet need of older adults with Dementia-Related psychosis. Front Pharmacol. 2020;11:87.","journal-title":"Front Pharmacol"},{"key":"879_CR305","doi-asserted-by":"crossref","unstructured":"Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Barbateskovic M et al. Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis. BMJ Ment Health. 2024;27(1).","DOI":"10.1136\/bmjment-2023-300730"},{"issue":"3","key":"879_CR306","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/neurolint13030038","volume":"13","author":"AN Edinoff","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, et al. Selective serotonin reuptake inhibitors and adverse effects: A narrative review. Neurol Int. 2021;13(3):387\u2013401.","journal-title":"Neurol Int"},{"issue":"4","key":"879_CR307","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/neurolint13040049","volume":"13","author":"D Fanelli","year":"2021","unstructured":"Fanelli D, Weller G, Liu H. New Serotonin-Norepinephrine reuptake inhibitors and their anesthetic and analgesic considerations. Neurol Int. 2021;13(4):497\u2013509.","journal-title":"Neurol Int"},{"issue":"7","key":"879_CR308","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/NEN.0b013e31817d7a1d","volume":"67","author":"H Fujishiro","year":"2008","unstructured":"Fujishiro H, Ferman TJ, Boeve BF, Smith GE, Graff-Radford NR, Uitti RJ, et al. Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol. 2008;67(7):649\u201356.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"879_CR309","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/jnnp.67.4.492","volume":"67","author":"D Aarsland","year":"1999","unstructured":"Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, et al. Range of neuropsychiatric disturbances in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1999;67(4):492\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"879_CR310","doi-asserted-by":"crossref","unstructured":"Haddad F, Sawalha M, Khawaja Y, Najjar A, Karaman R. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson\u2019s Disease. Molecules. 2017;23(1).","DOI":"10.3390\/molecules23010040"},{"issue":"2","key":"879_CR311","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"JP Taylor","year":"2020","unstructured":"Taylor JP, McKeith IG, Burn DJ, Boeve BF, Weintraub D, Bamford C, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2):157\u201369.","journal-title":"Lancet Neurol"},{"issue":"9","key":"879_CR312","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/jnnp.2004.052332","volume":"76","author":"S Molloy","year":"2005","unstructured":"Molloy S, McKeith IG, O\u2019Brien JT, Burn DJ. The role of Levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"879_CR313","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000331527","volume":"27","author":"T Ferman","year":"2012","unstructured":"Ferman T, Boeve B. Sleep in Parkinson\u2019s disease and dementia with Lewy bodies. Adv Biol Psychiatry. 2012;27:61\u201370.","journal-title":"Adv Biol Psychiatry"},{"issue":"1","key":"879_CR314","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5664\/jcsm.27717","volume":"6","author":"RN Aurora","year":"2010","unstructured":"Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85\u201395.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"879_CR315","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1389-9457(03)00072-8","volume":"4","author":"BF Boeve","year":"2003","unstructured":"Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med. 2003;4(4):281\u20134.","journal-title":"Sleep Med"},{"issue":"5\u20136","key":"879_CR316","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000471507","volume":"43","author":"MI Lapid","year":"2017","unstructured":"Lapid MI, Kuntz KM, Mason SS, Aakre JA, Lundt ES, Kremers W, et al. Efficacy, safety, and tolerability of Armodafinil therapy for hypersomnia associated with dementia with Lewy bodies: A pilot study. Dement Geriatr Cogn Disord. 2017;43(5\u20136):269\u201380.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"9","key":"879_CR317","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, et al. Treatment of central disorders of hypersomnolence: an American academy of sleep medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881\u201393.","journal-title":"J Clin Sleep Med"},{"issue":"5 Suppl","key":"879_CR318","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1177\/02537176211033316","volume":"43","author":"A Gupta","year":"2021","unstructured":"Gupta A, Prakash NB, Sannyasi G. Rehabilitation in dementia. Indian J Psychol Med. 2021;43(5 Suppl):S37\u201347.","journal-title":"Indian J Psychol Med"},{"key":"879_CR319","doi-asserted-by":"publisher","first-page":"4141050","DOI":"10.1155\/2019\/4141050","volume":"2019","author":"MB Ravn","year":"2019","unstructured":"Ravn MB, Petersen KS, Thuesen J. Rehabilitation for people living with dementia: A scoping review of processes and outcomes. J Aging Res. 2019;2019:4141050.","journal-title":"J Aging Res"},{"key":"879_CR320","doi-asserted-by":"publisher","first-page":"7856823","DOI":"10.1155\/2018\/7856823","volume":"2018","author":"B Langhammer","year":"2018","unstructured":"Langhammer B, Bergland A, Rydwik E. The importance of physical activity exercise among older people. Biomed Res Int. 2018;2018:7856823.","journal-title":"Biomed Res Int"},{"issue":"1","key":"879_CR321","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12877-019-1175-2","volume":"19","author":"RX Jia","year":"2019","unstructured":"Jia RX, Liang JH, Xu Y, Wang YQ. Effects of physical activity and exercise on the cognitive function of patients with Alzheimer disease: a meta-analysis. BMC Geriatr. 2019;19(1):181.","journal-title":"BMC Geriatr"},{"issue":"2","key":"879_CR322","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/09602010244000020","volume":"12","author":"BA Wilson","year":"2002","unstructured":"Wilson BA. Towards a comprehensive model of cognitive rehabilitation. Neuropsychological Rehabilitation. 2002;12(2):97\u2013110.","journal-title":"Neuropsychological Rehabilitation"},{"issue":"5","key":"879_CR323","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/gps.5076","volume":"34","author":"L Clare","year":"2019","unstructured":"Clare L, Kudlicka A, Oyebode JR, Jones RW, Bayer A, Leroi I, et al. Individual goal-oriented cognitive rehabilitation to improve everyday functioning for people with early-stage dementia: A multicentre randomised controlled trial (the GREAT trial). Int J Geriatr Psychiatry. 2019;34(5):709\u201321.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"879_CR324","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jgs.15660","volume":"67","author":"W Zhang","year":"2019","unstructured":"Zhang W, Low LF, Gwynn JD, Clemson L. Interventions to improve gait in older adults with cognitive impairment: A systematic review. J Am Geriatr Soc. 2019;67(2):381\u201391.","journal-title":"J Am Geriatr Soc"},{"key":"879_CR325","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/1471-2318-14-73","volume":"14","author":"M Schwenk","year":"2014","unstructured":"Schwenk M, Zieschang T, Englert S, Grewal G, Najafi B, Hauer K. Improvements in gait characteristics after intensive resistance and functional training in people with dementia: a randomised controlled trial. BMC Geriatr. 2014;14:73.","journal-title":"BMC Geriatr"},{"issue":"1","key":"879_CR326","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000529256","volume":"52","author":"L Guidi","year":"2023","unstructured":"Guidi L, Evangelisti S, Siniscalco A, Lodi R, Tonon C, Mitolo M. Non-Pharmacological treatments in Lewy body disease: A systematic review. Dement Geriatr Cogn Disord. 2023;52(1):16\u201331.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"1","key":"879_CR327","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/gps.4529","volume":"32","author":"R Cheston","year":"2017","unstructured":"Cheston R, Ivanecka A. Individual and group psychotherapy with people diagnosed with dementia: a systematic review of the literature. Int J Geriatr Psychiatry. 2017;32(1):3\u201331.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10","key":"879_CR328","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.parkreldis.2013.05.010","volume":"19","author":"J Horvath","year":"2013","unstructured":"Horvath J, Herrmann FR, Burkhard PR, Bouras C, K\u00f6vari E. Neuropathology of dementia in a large cohort of patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19(10):864\u20138. discussion 864.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"879_CR329","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00401-021-02383-3","volume":"143","author":"MT Uemura","year":"2022","unstructured":"Uemura MT, Robinson JL, Cousins KAQ, Tropea TF, Kargilis DC, McBride JD, et al. Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease. Acta Neuropathol. 2022;143(1):15\u201331.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"879_CR330","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMp1208061","volume":"367","author":"L Yang","year":"2012","unstructured":"Yang L, Rieves D, Ganley C. Brain amyloid imaging\u2013FDA approval of Florbetapir F18 injection. N Engl J Med. 2012;367(10):885\u20137.","journal-title":"N Engl J Med"},{"issue":"10","key":"879_CR331","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2967\/jnumed.120.252254","volume":"61","author":"VS Mattay","year":"2020","unstructured":"Mattay VS, Fotenos AF, Ganley CJ, Marzella L. Brain Tau imaging: food and drug administration approval of (18)F-Flortaucipir injection. J Nucl Med. 2020;61(10):1411\u20132.","journal-title":"J Nucl Med"},{"key":"879_CR332","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3389\/fnins.2018.00585","volume":"12","author":"R Harada","year":"2018","unstructured":"Harada R, Okamura N, Furumoto S, Yanai K. Imaging protein misfolding in the brain using \u03b2-Sheet ligands. Front Neurosci. 2018;12:585.","journal-title":"Front Neurosci"},{"issue":"16","key":"879_CR333","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1016\/j.cell.2023.06.004","volume":"186","author":"J Xiang","year":"2023","unstructured":"Xiang J, Tao Y, Xia Y, Luo S, Zhao Q, Li B, et al. Development of an \u03b1-synuclein positron emission tomography tracer for imaging synucleinopathies. Cell. 2023;186(16):3350\u2013e33673319.","journal-title":"Cell"},{"issue":"1","key":"879_CR334","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith R, Capotosti F, Schain M, Ohlsson T, Vokali E, Molette J, et al. The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun. 2023;14(1):6750.","journal-title":"Nat Commun"},{"key":"879_CR335","doi-asserted-by":"crossref","unstructured":"Endo H, Ono M, Takado Y, Matsuoka K, Takahashi M, Tagai K et al. Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron. 2024.","DOI":"10.1016\/j.neuron.2024.05.006"},{"key":"879_CR336","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.brainres.2008.11.055","volume":"1251","author":"M Noguchi-Shinohara","year":"2009","unstructured":"Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, Nakagawa M, et al. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer\u2019s disease. Brain Res. 2009;1251:1\u20136.","journal-title":"Brain Res"},{"issue":"2","key":"879_CR337","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1017\/S1041610209991049","volume":"22","author":"C Ballard","year":"2010","unstructured":"Ballard C, Jones EL, Londos E, Minthon L, Francis P, Aarsland D. alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. Int Psychogeriatr. 2010;22(2):321\u20137.","journal-title":"Int Psychogeriatr"},{"issue":"18","key":"879_CR338","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1212\/WNL.0b013e3182a9f449","volume":"81","author":"N Wang","year":"2013","unstructured":"Wang N, Gibbons CH, Lafo J, Freeman R. \u03b1-Synuclein in cutaneous autonomic nerves. Neurology. 2013;81(18):1604\u201310.","journal-title":"Neurology"},{"key":"879_CR339","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13601-019-0262-y","volume":"9","author":"KY Baumann","year":"2019","unstructured":"Baumann KY, Church MK, Clough GF, Quist SR, Schmelz M, Skov PS, et al. Skin microdialysis: methods, applications and future opportunities-an EAACI position paper. Clin Transl Allergy. 2019;9:24.","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"879_CR340","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s44222-023-00108-7","volume":"2","author":"LK Vora","year":"2024","unstructured":"Vora LK, Sabri AH, McKenna PE, Himawan A, Hutton ARJ, Detamornrat U, et al. Microneedle-based biosensing. Nat Reviews Bioeng. 2024;2(1):64\u201381.","journal-title":"Nat Reviews Bioeng"},{"issue":"6","key":"879_CR341","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1074\/jbc.M310994200","volume":"279","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Kim YM, Lee G, Junn E, Iwatsubo T, Mouradian MM. Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J Biol Chem. 2004;279(6):4625\u201331.","journal-title":"J Biol Chem"},{"issue":"2","key":"879_CR342","doi-asserted-by":"publisher","first-page":"R78","DOI":"10.1016\/j.cub.2003.12.051","volume":"14","author":"A Mogk","year":"2004","unstructured":"Mogk A, Bukau B. Molecular chaperones: structure of a protein disaggregase. Curr Biol. 2004;14(2):R78\u201380.","journal-title":"Curr Biol"},{"issue":"1","key":"879_CR343","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molcel.2004.06.029","volume":"15","author":"G Schaffar","year":"2004","unstructured":"Schaffar G, Breuer P, Boteva R, Behrends C, Tzvetkov N, Strippel N, et al. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol Cell. 2004;15(1):95\u2013105.","journal-title":"Mol Cell"},{"issue":"1","key":"879_CR344","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.jmb.2003.12.013","volume":"336","author":"S Schlee","year":"2004","unstructured":"Schlee S, Beinker P, Akhrymuk A, Reinstein J. A chaperone network for the resolubilization of protein aggregates: direct interaction of ClpB and DnaK. J Mol Biol. 2004;336(1):275\u201385.","journal-title":"J Mol Biol"},{"key":"879_CR345","doi-asserted-by":"publisher","first-page":"155101","DOI":"10.1016\/j.phymed.2023.155101","volume":"121","author":"D Cui","year":"2023","unstructured":"Cui D, Chen Y, Ye B, Guo W, Wang D, He J. Natural products for the treatment of neurodegenerative diseases. Phytomedicine. 2023;121:155101.","journal-title":"Phytomedicine"},{"issue":"1","key":"879_CR346","doi-asserted-by":"publisher","first-page":"12827","DOI":"10.1038\/s41598-020-69744-y","volume":"10","author":"A Dominguez-Meijide","year":"2020","unstructured":"Dominguez-Meijide A, Vasili E, K\u00f6nig A, Cima-Omori MS, Ib\u00e1\u00f1ez de Opakua A, Leonov A, et al. Effects of Pharmacological modulators of \u03b1-synuclein and Tau aggregation and internalization. Sci Rep. 2020;10(1):12827.","journal-title":"Sci Rep"},{"issue":"6740","key":"879_CR347","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173\u20137.","journal-title":"Nature"},{"issue":"5","key":"879_CR348","doi-asserted-by":"publisher","first-page":"103974","DOI":"10.1016\/j.drudis.2024.103974","volume":"29","author":"A Mukherjee","year":"2024","unstructured":"Mukherjee A, Biswas S, Roy I, Immunotherapy. An emerging treatment option for neurodegenerative diseases. Drug Discov Today. 2024;29(5):103974.","journal-title":"Drug Discov Today"},{"issue":"1","key":"879_CR349","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"879_CR350","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS, Coelho T, Plant\u00e9-Bordeneuve V, Berk JL, et al. Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1\u20139.","journal-title":"Amyloid"},{"issue":"1","key":"879_CR351","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"}],"updated-by":[{"DOI":"10.1186\/s13024-025-00902-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000}}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00879-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-025-00879-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-025-00879-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:29:54Z","timestamp":1781605794000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13024-025-00879-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":351,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1186\/s13024-025-00879-0","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13024-025-00902-4","URL":"https:\/\/doi.org\/10.1186\/s13024-025-00902-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}